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Abstract 
 
Bacterial and viral infections affect billions of people each year. While bacterial 
infections are treated by the use of antibiotics, viral infections are eradicated by 
the immune system. This thesis comprises two parts. Part I presents the 
reconstitution of enzymes required for the synthesis of the minimal 
pharmacophore of moenomycin A (MmA), a molecule with antibacterial activity. 
Part II details single-particle electron microscopy studies of MDA5 alone and in 
complex with double-stranded RNA (dsRNA).  
MmA is a natural product antibiotic from Streptomyces ghanaensis that 
possesses remarkable potency against clinically relevant Gram-positive bacteria. 
MmA exerts its antibacterial activity by binding directly to peptidoglycan 
glycosyltransferases, enzymes involved in the synthesis of the glycan strands of 
peptidoglycan. The genes responsible for MmA biosynthesis have been identified, 
and a complete biosynthetic pathway has been proposed. Part I of this thesis 
describes the reconstitution of enzymes required for the synthesis of two 
trisaccharide scaffolds of MmA that retain antibacterial activity. It also describes 
the synthesis of unnatural phosphoglycerate lipid acceptors and UDP-amino 
sugars that can be used to probe the substrate tolerances of key 
glycosyltransferases in MmA biosynthesis. This work lays the foundation for the 
iv 
	  
synthesis of unnatural MmA analogs that may possess better pharmacokinetic 
properties than the parent molecule. 
MDA5 is a helicase that detects viral dsRNA in the cytoplasm of 
vertebrate cells.  Upon dsRNA recognition, MDA5 initiates a series of signal 
transduction events that activate the innate immune response. Part II of this thesis 
presents the structures of apo MDA5 protein and the MDA5-dsRNA complex 
obtained by using single-particle electron microscopy. Two-dimensional averages 
of apo MDA5 revealed that the protein is very flexible and can adopt multiple 
conformations. This finding suggests that MDA5 does not adopt an autorepressed 
conformation in the absence of viral dsRNA. When MDA5 is incubated with 
dsRNA, the protein assembles onto the dsRNA to form a linear oligomer. Two-
dimensional averages and a three-dimensional reconstruction reveal the complex 
to consist of seven to eight stacked discs per strand of 112 base pair dsRNA. This 
work lays the foundation for further structural studies aimed at elucidating the 
mechanism by which MDA5 is activated. 
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Chapter 1: Introduction to moenomycin and MDA5 
Bacterial and viral infections affect billions of people every year. While bacterial 
infections are treated by the administration of antibiotics, most viral infections can 
be eradicated by the innate immune response (Dasgupta, 2012). This thesis 
consists of two parts, the first one describing efforts towards the development of 
new antibiotics and the second one describing research to advance our 
understanding of the innate immune system.  
Part I of this thesis (Chapters 2-4) is concerned with the characterization 
of the biosynthetic pathway of moenomycin A (MmA) and the involved enzymes. 
MmA, a natural product produced by Streptomyces ghanaensis, exhibits potent 
antibacterial activity against a diverse range of gram-positive bacteria 
(Wallhausser et al, 1965; Slusarchyk et al, 1971). Interest in MmA has surged in 
the past 25 years as the rapid development of resistance to existing antibiotics 
prompted a renewed search for novel molecules with antibacterial potency (Bren, 
2002; Halliday et al, 2006). MmA harbors great promise, because it prevents the 
synthesis of peptidoglycan, a structure that is essential for bacterial survival and 
growth (Bugg, 1999; Halliday et al, 2006). MmA also represents a novel 
structural class of antibacterials that poses no risk towards the development of 
cross-resistance from existing antibiotics (Halliday et al, 2006). Even though it 
exhibits impressive potency, MmA has not been developed for use in humans, 
because the molecule has poor pharmacokinetic properties (Wasielewski et al, 
1965). Chapter 2 of this thesis provides a general introduction to MmA and 
summarizes major research findings. Chapter 3 presents genetic experiments 
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performed to characterize the biosynthetic pathway of MmA. Chapter 4 describes 
efforts toward the reconstitution of enzymes required for the synthesis of the 
minimal pharmacophore of MmA, and also lays out initial research performed to 
produce novel analogs of MmA. Taken together, the research described in the first 
part of this thesis is aimed at developing a rapid method for the chemenzymatic 
synthesis of MmA analogs with improved pharmacokinetic properties.  
Part II of this thesis (Chapters 5-7) is concerned with the biochemical and 
structural characterization of MDA5, an enzyme that detects non-self, double-
stranded RNA (dsRNA). dsRNA is the genetic material of many RNA viruses and 
elicits a powerful innate immune response in vertebrate organisms (Wang et al, 
2011). Effective immune defense depends on the rapid recognition of viral 
dsRNA by pattern recognition receptors, of which there are two major classes. 
The toll-like receptors (TLRs) are integral membrane proteins that detect 
phagocytosed viral components in the extracelluar matrix (Schulz et al, 2005). 
The RIG-I-like receptors, RIG-I and MDA5, are helicases that detect foreign 
dsRNA in the cytoplasm of cells (Wilkins et al, 2010). Upon activation, RIG-I 
and MDA5 interact with a common signaling adaptor protein, mitochondria 
antiviral-signaling protein (MAVS), which ultimately leads to the expression of 
type I interferons and proinflammatory cytokines (Rehwinkel et al, 2010). While 
much effort focused on understanding the mechanism and structure of RIG-I, little 
work has addressed MDA5. Chapter 5 introduces the innate immune system with 
an emphasis on our current knowledge of RIG-I and MDA5, and Chapters 6 and 7 
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present biochemical and structural studies of the mechanism that underlies MDA5 
activation. 
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Chapter 2: Introduction to moenomycin A and the peptidoglycan 
glycosyltransferases 
 
2.1: The problem of antibiotic resistance 
The discovery of antibiotics in the early 20th century revolutionized the medical 
sciences and prolonged human life. Before this discovery, patients with any form 
of bacteremia had very little chance of survival. In 1970, the Surgeon General of 
the United States declared that infectious diseases were no longer a major health 
threat and stipulated research efforts to be redirected to emerging frontiers of 
health issues (Breithaupt, 1999). Since then, however, resistance to available 
antibiotics has emerged, and the search for novel antibiotics has been reasserted 
as a pressing medical need. Today, five to ten percent of hospital patients develop 
bacterial infections, and 70 percent of the causative pathogens exhibit resistance 
to at least one of the antibiotics in current use (Bren, 2002).  
Amongst all bacteremia-causing pathogens, Staphylococcus aureus has 
emerged as the leading cause of life-threatening infections in hospitals and the 
community (Gould, 2006; Taubes, 2008). S. aureus is highly virulent and can 
spread simply by contact (Boucher et al, 2008; Stryjewski et al, 2008). The 
bacteria also infect burn and surgical wounds and thus are endemic in hospitals. S. 
aureus has the propensity to develop resistance towards antibiotics, however, and 
methicillin-resistant S. aureus (MRSA) appeared in the United States in 1981. 
Since then, invasive MRSA infection has become widespread in hospitals and 
 6 
accounts for more deaths in the United States than that from AIDS, tuberculosis 
and viral hepatitis combined (Klevens et al, 2007; Boucher, 2008). 
For a period of time, MRSA infections could be treated with the 
glycopeptide vancomycin, commonly known as the last line of defense against 
MRSA. In 2002, however, a high level vancomycin-resistant MRSA (VRSA) 
strain was isolated from a dialysis patient in Michigan (Weigel et al, 2003). This 
VRSA strain harbored a plasmid that encoded resistance genes for vancomycin, 
trimethoprim, aminoglycosides, beta-lactams, and disinfectants (Ferber, 2003; 
Weigel et al, 2003). It is believed that this MRSA strain has acquired vancomycin 
resistance from vancomycin-resistant enterococci, which have become common 
in the 1980s. Since then, a handful of additional cases of VRSA have been 
documented (Bozdogan et al, 2003; Lowy, 2003; Pfeltz et al, 2004; Walsh et al, 
2004). Although several of these cases involve common features (feet wounds), 
they are believed to be epidemiologically unrelated events. The emergence and 
spread of VRSA in the community is now inevitable, and the development of 
antibiotics to treat these infections is a high priority (Coates et al, 2002; Brown et 
al, 2005). 
The introduction of linezolid, cubicin (daptomycin), and tigecycline into 
clinical use affords some short-term security against resistant pathogens. The 
oxazolidinone linezolid was approved in 2000 for the treatment of resistant 
bacterial infections, including those caused by MRSA and vancomycin-resistant 
enterococci (VRE) (Clemett et al, 2000; Brickner et al, 2008). However, 
resistance to linezolid has already developed, although the frequency of such 
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occurrences remains low (Tsiodras et al, 2001; Meka et al, 2004a; Meka et al, 
2004b). Cubicin is a natural product antibiotic that was introduced in 2003 to treat 
skin and soft tissue infections caused by MRSA (Kirkpatrick et al, 2003). Like 
linezolid, resistance against cubicin developed quickly and a cubicin-resistant 
MRSA strain has already appeared in the clinic (Skiest et al, 2006). More 
recently, in 2005, the tetracycline derivative tigecycline was made available after 
fast-track approval by the FDA. However, since it is a structural analog of the 
tetracycline family of antibiotics, cross-resistance is expected to become an issue 
in the near-term future (Silver, 2003). The projected dearth of available treatments 
against resistant VRSA infections in the future makes the development of 
antibiotics that belong to novel structural classes or bind to new protein targets an 
urgent medical need. 
 
2.2: Peptidoglycan biosynthesis: a validated target for antibiotic action 
Peptidoglycan biosynthesis is a validated pathway for antibiotic action, because it 
is essential for bacterial growth and survival and is conserved even amongst 
organisms whose evolution diverged a billion years ago (Bugg, 1999). It is thus 
one of four metabolic pathways traditionally targeted by antibacterial drugs. The 
other three pathways are bacterial protein biosynthesis, DNA replication and 
repair, and folate coenzyme biosynthesis (Walsh, 2003).  
Peptidoglycan is an essential, cross-linked polymer composed of 
carbohydrate and peptide units that prevent bacterial cells from lysing due to high 
internal osmotic pressures. It is biosynthesized in three stages. The first two stages 
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occur on the cytoplasmic side of the bacterial inner membrane and consist of the 
formation of Lipid II, a lipid-linked disaccharide pentapeptide molecule, from 
UDP-N-acetyl-glucosamine (UDP-GlcNAc) (Bugg et al, 1992; van Heijenoort, 
2001). It is then flipped to the outside of the plasma membrane, where the 
disaccharide is polymerized into glycan chains by peptidoglycan 
glycosyltrasnferases (PGTs, also known as transglycosylases TG), and the 
pentapeptide is cross-linked by transpeptidases (TPs) (Koch, 2000; van 
Heijenoort, 2001). PGT and TP activities can either be mediated by two distinct 
proteins or sometimes by two separate domains of one bifunctional enzyme.  
The formation of mature peptidoglycan from Lipid II on the extracellular 
side of the bacterial plasma membrane is a particularly good drug target. First, 
since the process is extracellular, drugs targeted at gram-positive pathogens will 
not have to cross any membrane barriers, allowing greater variability in the size 
and charge of the potential drug. This localization also allows the drug to evade 
efflux pumps that actively transport toxic substances from the cells’ interior into 
the extracellular environment (Webber et al, 2003). Second, bacteria have 
multiple PGTs and TPs encoded by different genes (Zapun et al, 2012). The 
emergence of resistance against drugs that target these enzymes should thus be 
slow, since multiple spontaneous mutations must occur before all PGTs and TPs 
become unresponsive to the drug (Silver, 2007). Finally, since peptidoglycan is 
unique to bacterial cells, there is nearly no risk that a drug can elicit an 
autoimmune response by cross-reacting with a similar human enzyme.  
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The targeting of the final step of peptidoglycan biosynthesis by antibiotics 
is validated by the large number of antibacterials that block this step. Penicillin 
and other beta-lactams (cephalosporins, monobactams, and cabapenems) inhibit 
peptide cross-linking by binding to the transpeptidases (Essack, 2001; Fisher et al, 
2005), vancomycin blocks mature peptidoglycan formation by sequestering Lipid 
II (Breukink et al, 2006), and finally, compounds of the moenomycin family bind 
to the PGTs, thus preventing the polymerization of glycan chains (Huber et al, 
1968; Jackson et al, 1984). 
 
2.3: Moenomycin A 
Moenomycin A (MmA) is a phosphoglycolipid natural product produced by 
Streptomyces ghanaensis. It is one of more than ten structurally similar 
compounds isolated from the Streptomyces species in the 1960s (Wallhausser et 
al, 1965). MmA is composed of an isoprene-derived C25 lipid tail (moenocinol) 
attached through a phosphoglycerate linkage to a pentasaccharide that is 
covalently linked to a 1-amino-2,5-dioxocyclopentane moiety (Figure 2.1). Other 
phosphoglycolipid natural products have similar scaffold structures with minor 
differences in the lipid and pentasaccharide regions (Torikata et al, 1977). 
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Figure 2.1: Chemical structure of moenomycin A. 
 
2.4: Structure-activity relationship studies 
MmA displays impressive activity against a broad spectrum of Gram-positive 
bacteria, including bacilli, staphylococci (and MRSA), streptococci, and 
diplococci. The minimum inhibitory concentration (MIC) values reported for 
MmA are 10-1000 lower than that for vancomycin (Slusarchyk et al, 1971; 
Halliday et al, 2006). Despite its potency, however, MmA has never been 
developed for human use because the molecule displays poor pharmacokinetic 
properties (Wasielewski et al, 1965; Halliday et al, 2006). It has, however, been 
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commercialized and used successfully for many years as a growth promoter in 
animal feed (Pfaller, 2006). 
Interest in developing MmA as an antibacterial drug for human use has 
surged in the last 25 years. To improve the pharmacokinetic properties of the 
molecule, extensive structure-activity relationship (SAR) studies have been 
performed. Welzel and colleagues performed extensive synthesis and degradation 
studies of MmA to define the minimum active unit (El-Abadla et al, 1999; Welzel 
et al, 1984; Welzel et al, 1987). These studies concluded that the disaccharide unit 
consisting of the E and F glycan rings has full activity (when compared with 
MmA) as a PGT inhibitor. Unexpectedly, the disaccharide analog with an F-ring 
4’-H replacing the 4’-methyl group exhibited full inhibitory activity as well (El-
Abadla et al, 1999). This result indicated that the axial methyl group on the F-ring 
is not involved in eliciting binding energy. Welzel also showed that the carbamate 
at C3 of the F-ring, the acetyl group at C2 of the E-ring, and the phosphoglycerate 
moiety are required for inhibitory activity (1987). Since Welzel obtained 
disaccharide and trisaccharide products through chemical degradation, all analogs 
contained a fully saturated C25 lipid tail. This is due to the labile nature of the 
double bond, which Welzel hydrogenated in the first step of his degradation 
studies (1984). The role of the lipid structure in enzyme inhibition was not studied 
until 2006, when Kahne and coworkers designed a degradation scheme that 
enabled the detachment of the C25 moenocinol lipid and the reattachment of any 
synthetic lipid to the pentasaccharide core (Adachi et al, 2006). By doing so, they 
found that the enzyme inhibitory activity of neryl-MmA (MmA with a C10 neryl 
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lipid tail) is comparable to that of the parent molecule. However, the MIC of 
neryl-MmA against S. aureus and E. facalis are a few orders higher than for 
MmA (Adachi et al, 2006). This result indicates that 10 carbon units is the 
minimum lipid length required for full enzyme inhibition in the absence of 
membrane and detergent. The reason for why a longer lipid is required for 
biological activity may be that longer lipids enhance the ability of the molecule to 
partition into biological membranes (Marzian et al, 1994; Volke et al, 1997). 
The extensive amount of SAR knowledge that has been gathered on MmA 
aids its development as an antibiotic for human use. Recent years have also seen 
the development of a strategy for the total synthesis of MmA, enabling further 
flexibility and variety in analog design (Taylor et al, 2006). The recent 
identification of the MmA gene cluster from S. ghanaensis opens yet another new 
avenue for accessing novel bioactive compounds that may be used in conjunction 
with chemical synthesis and degradation (Ostash et al, 2007). The next two 
chapters of this thesis discuss the characterization and initial reconstitution efforts 
of the MmA biosynthetic enzymes.  
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Chapter 3: Complete characterization of the seventeen step moenomycin 
biosynthetic pathway 
 
This chapter is a reprint of the following publication: Ostash, B., Doud, E., Lin, 
C., Ostash, I., Perlstein, D., Fuse, S., Wolpert, M., Kahne, D., and Walker, S. 
(2009) Complete characterization of the seventeen step moenomycin biosynthetic 
pathway. Biochem 48:8830-8841. I contributed to this work by reconstituting 
MoeGT1 and MoeE5 and testing their biochemical activities. The supplemental 
information that accompanies this publication is not reprinted here due to its large 
size.  
 
 
The moenomycins are phosphoglycolipid antibiotics produced by Streptomyces 
ghanaensis and related organisms. The phosphoglycolipids are the only known 
active site inhibitors of the peptidoglycan glycosyltransferases, an important 
family of enzymes involved in the biosynthesis of the bacterial cell wall. 
Although these natural products have exceptionally potent antibiotic activity, 
pharmacokinetic limitations have precluded their clinical use. We previously 
identified the moenomycin biosynthetic gene cluster in order to facilitate 
biosynthetic approaches to new derivatives. Here, we report a comprehensive set 
of genetic and enzymatic experiments that establish functions for the 17 
moenomycin biosynthetic genes involved in the synthesis of moenomycin and 
variants. These studies reveal the order of assembly of the full molecular scaffold 
and define a subset of seven genes involved in the synthesis of bioactive 
analogues. This work will enable both in vitro and fermentation-based 
reconstitution of phosphoglycolipid scaffolds so that chemoenzymatic approaches 
to novel analogues can be explored. 
 18 
3.1: Introduction 
Peptidoglycan glycosyltransferases (PGTs) are a family of enzymes that assemble 
the glycan chains of the bacterial cell wall from disaccharide precursors 
(Goldman et al, 2000; Ostash et al, 2005). They are potentially important 
antibacterial targets because their functions are essential, their structures are 
highly conserved, they have no eukaryotic counterparts, and peptidoglycan 
biosynthesis is a well-validated pathway for antibiotics (Ostash et al, 2005; 
Halliday et al, 2006; Wright, 2007). Although there are not yet any clinically used 
antibiotics that target these enzymes, a family of natural products called the 
phosphoglycolipids inhibit the PGTs and have potent antibacterial activity against 
Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus 
and both vancomycin-sensitive and vancomycin-resistant pathogens (Goldman et 
al, 2000; Ostash et al, 2005; Welzel, 2005). 
Moenomycin A (1) (MmA, Figure 3.1a) is the prototypical member of the 
phosphoglycolipid family of antibiotics. It has been widely used as an animal 
growth promoter but was never developed for human use because it has poor 
physicochemical properties, including a very long half-life that is presumed to be 
related to the long lipid chain on the molecule (Adachi et al, 2006). It may be 
possible to develop phosphoglycolipid analogues that have better properties than 
MmA by altering particular structural features. Recently reported structures of co-
complexes of PGTs with bound moenomycin and neryl-moenomycin provide 
information on the mode of binding and on critical protein-ligand contacts, which 
should facilitate efforts to design analogues (Lovering et al, 2007; Yuan et al, 
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2007; Lovering et al, 2008; Yuan et al, 2008; Heaslet et al, 2009; Sung et al, 
2009). The challenge now is to develop approaches to make a wide range of 
analogues efficiently so that the potential of the phosphoglycolipid antibiotics can 
be explored (Goldman et al, 2000; Ostash et al, 2005; Welzel, 2005). 
Efforts to synthesize MmA analogues go back many years, and the total 
synthesis of MmA was reported in 2006 (Goldman et al, 2000; Ostash et al, 2005; 
Welzel, 2005; Adachi et al, 2006; Taylor et al, 2006). Thus, fully synthetic 
approaches to make analogues are available. However, the total chemical 
synthesis of MmA analogues remains an inefficient process because of the 
structural complexity of the molecule (Adachi et al, 2006; Taylor et al, 2006). 
Biosynthetic or chemoenzymatic approaches provide an alternate, potentially 
more efficient means, to produce analogues. With this possibility in mind, we 
recently sequenced the producing organism, Streptomyces ghanaensis, in order to 
identify the genes involved in MmA biosynthesis (Ostash et al, 2007). We 
proposed functions for many of the biosynthetic genes based on sequence 
analysis, but experimental validation of these functions was not completed. 
Furthermore, specific functions were not assigned for the five putative 
glycosyltransferases that make the pentasaccharide, the direction of 
pentasaccharide assembly was not established, the order of the tailoring 
modifications was unknown, and the genes involved in the biosynthesis of 
biologically active scaffolds were not identified. Here, we report a comprehensive 
set of genetic and enzymatic experiments that illuminate the moenomycin 
biosynthetic pathway. This work lays the foundation for the development of 
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chemoenzymatic approaches to the synthesis of new PGT inhibitors. 
 
 
Figure 3.1: Key structures and DNA constructs. (a) Structure of moenomycin 
A (1, MmA). (b) Phosphoglycolipid derivatives of moenomycin: 2 
(pholipomycin) produced by strain moeno38-1+pOOB64b+; 3 produced by cosmid 
moeno38-1; 4 produced by moeno38-1+ΔmoeK5; 5 and 6 produced by moeno38-
1+ΔmoeN5. 
 
 
3.2: Materials and methods 
Antibiotics. Pure MmA was provided by M. Adachi (Dept. of Chemistry and 
Chemical Biology, Harvard University). The following concentrations of 
commercially available antibiotics were used for strain selection (µg/mL): 
ampicillin (100), carbenicillin (100), chloramphenicol (35), kanamycin (50), 
apramycin (50), hygromycin (100), spectinomycin (200), streptomycin (100), 
thiostrepton (50), and nalidixic acid (50) (Sigma-Aldrich). UDP-GlcUA was 
purchased from Sigma-Aldrich. Isoprenoid pyrophosphates were purchased from 
Isoprenoids, Lc. 
 
Strains and vector DNAs. Streptomyces ghanaensis ATCC14672 and Bacillus 
cereus ATCC19637 were obtained from ATCC. S. lividans TK24 was kindly 
provided by M. Kobayashi (University of Tsukuba, Japan). The methylation-
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deficient conjugative strain E. coli ET12567 (pUB307) (Flett et al, 1997) was 
obtained from Professor C. P. Smith (Manchester University, U.K.). E. coli 
BW25113 (pIJ790) was obtained from the John Innes Center (Norwich, U.K.). 
The S. ghanaensis strain MO12, which contains a disrupted moeGT3 gene, and 
the S. lividans strains expressing various subsets of moe genes were constructed in 
this work. The vectors pKC1139, pSET152, pMKI9, and pOOB40 were obtained 
as described previously (Ostash et al, 2007). Plasmid pWQ67 was obtained from 
Professor C. Whitfield (University of Guelph, Canada) for the expression of 
epimerase GlaKP (Frirdich et al, 2005). The integrative vector pSOK804 
(Sekurova et al, 2004) was a gift from S. Zotchev (Norwegian University of 
Science and Technology, Trondheim, Norway). The expression vector pAF1 
(oripIJ101 bla tsr, PermE*, 6His tag) was provided by A. Bechthold (Freiburg 
University, Germany). Plasmids pKD4 and pCP20 (Datsenko et al, 2000) were 
obtained from J. Beckwith (Harvard Medical School, USA). The spectinomycin 
resistance cassette pHP45 (BlondeletRouault et al, 1997) was obtained from J.-L. 
Pernodet (Universite Paris-Sud, France). Plasmid pTB146 was obtained from 
T.G. Bernhardt (Harvard Medical School). 
 
Cloning of moeO5, moeE5, and moeGT1. The moeO5 gene was initially cloned 
into the pAF1 vector for expression as a N-terminal His6 fusion in S. lividans 
(pED2). An E. coli codon optimized moeO5 gene (synO5) was designed and 
synthesized by Mr.Gene. The gene was delivered in an ampicillin resistant 
plasmid named pMA_moeO5. SynO5 was PCR amplified from pMA_moeO5 
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using primers synO5SUMOf 
(TTGGTAGAAGAGCAGTTAACGCTAGTCCTCAACTG) and synO5SUMOr 
(CCCGGGTCAACGGCCAGAACC). These primers introduced the respective 
restriction enzyme sites SapI and XmaI (underlined). PCR amplification was 
performed with KOD Hot Start polymerase (Novagen). The PCR product was gel 
purified, digested with SapI and XmaI, and ligated using T4 DNA ligase (NEB) 
into the linearized expression plasmid pTB146 to give the N-terminal 
SUMO/His6-tagged pTBsynO5. 
MoeE5 was PCR amplified from cosmid moeno38-1 using primers 
MoeE5BamHI (AAAAAGGATCCGGTGTCGAGCGATACACACGG) and 
MoeE5XhoI (AAAAACTCGAGCTACAGCCGCGGCACGGAC), introducing 
BamHI and XhoI restriction sites, respectively (underlined). The PCR product 
was gel purified, digested with BamHI and XhoI, and ligated into linearized 
vector pET48b using T4 DNA ligase (NEB) to give N-terminal thioredoxin/His6-
tagged pET48b-MoeE5. 
MoeGT1 was PCR amplified from cosmid moeno38-1 using primers 
MoeGT1Nde1 (AAACATATGGCTGCCCCCGACCGAC) and MoeGT1NotI 
(ATAAAGCGGCCGCTCGGGCGTC), introducing NdeI and NotI restriction 
sites, respectively (underlined). The PCR product was gel purified, digested with 
NdeI and NotI, and ligated using T4 DNA ligase (NEB) into linearized vector 
pET24b to give N-terminal His6-tagged pET24b-MoeGT1. 
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Expression and purification of MoeO5, MoeE5, and MoeGT1. The pTBsynO5 
expression construct was transformed into BL21(DE3) competent cells 
(Invitrogen) for protein overproduction. pET48b-MoeE5 and pET24b-MoeGT1 
constructs were transformed into Rosetta2(DE3)pLysS (Novagen) competent cells 
for protein overproduction. Transformants harboring the desired constructs were 
grown at 37°C in LB containing 100 µg/mL carbenicillin (for pTBsynO5) or 50 
µg/mL kanamycin and 35 µg/mL cloramphenicol (for pET48b-MoeE5 and 
pET24b-MoeGT1) to an OD600 of 0.6. The temperature was reduced to 16°C, and 
the cells were induced by the addition of isopropyl-D-thiogalactopyranoside 
(IPTG) to a final concentration of 1 mM. After an additional 16 h at 16°C, the 
cells were harvested by centrifugation (20 min at 5000g) and frozen at -80°C. 
pTBsynO5 cells were resuspended in buffer A (50 mM Tris-HCl at pH 
7.5, 300 mM NaCl, 5 mM MgCl2, and 3% CHAPS) and incubated at room 
temperature with rlysozyme, benzonase, and protease inhibitor complexes 
(Novagen) for 1 h. Cells were then lysed by sonication, and the cell debris was 
removed by centrifugation (30 min at 14,000g). The supernatant was diluted with 
1.5 volumes buffer B (50 mM Tris-HCl at pH 7.5, 400 mM NaCl, and 5 mM 
MgCl2) and rocked with TALON resin (Clontech) for 1 h at 4°C. The resin was 
collected and washed with buffer B supplemented with 5 mM imidazole by 
rocking for 30 min at 4°C, packed into a column, and eluted with 20-200 mM 
imidazole in buffer B. Fractions containing the target protein (identified by 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)) were 
pooled, desalted, concentrated, flash frozen in liquid nitrogen, and stored at -
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80°C. The protein concentration was determined using the Dc Protein Assay 
(Biorad) using BSA as the standard. The yield of purified MoeO5 was 
approximately 4 mg/L. 
pET48b-MoeE5 and pET24b-MoeGT1 cell pellets were resuspended in 
buffer C (50 mM Tris-HCl at pH 7.5, 400 mM NaCl, 5 mM MgCl2, and 1% 
CHAPS) and D (25 mM Tris-HCl at pH 8, 200 mM NaCl, 5% glycerol, 0.5% 
CHAPS, and 20 mM imidazole), respectively, supplemented with rlysozyme, 
benzonase, and protease inhibitor complex (Novagen). After 1 h at room 
temperature, the cells were lysed by sonication, and the cell debris was removed 
by centrifugation (30 min at 14,000g). The supernatant was incubated with Ni-
NTA resin (Qiagen) for 30 min at 4°C. The recovered resin was washed with 
buffer C or D and packed into a column, and protein was eluted using a stepwise 
gradient of 5-500 mM imidazole. Fractions containing the target protein 
(identified by SDS-PAGE) were pooled, desalted, and concentrated. MoeE5 was 
flash frozen in liquid nitrogen in 20 mM Tris-HCl at pH 7.5, 150 mM NaCl, 10% 
glycerol and stored at -80°C. MoeGT1 was stored at 4°C in 20 mM Tris-HCl at 
pH 8, 10 mM MgCl2, 10 mM CaCl2, and 10% glycerol. The protein concentration 
was determined using the Dc Protein Assay (Biorad) using BSA as the standard. 
The purified yield for MoeE5 was approximately 15 mg/L. The purified yield for 
MoeGT1 was approximately 4 mg/L. 
 
Characterization of MoeO5. All LC/MS experiments were performed using a 
Phenomenex Gemini 5µ C18 100 Å column (50 mm x 4.6 mm) at a flow rate of 1 
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mL/min (solvent A: 95:5 water/methanol; solvent B, 60:35:5 
isopropanol/methanol/water both with 0.1% ammonium hydroxide as a solvent 
modifier). 
MoeO5 activity assays were performed in 50 mM Tris-HCl at pH 7.5, 300 
mM NaCl, 5 mM MgCl2 with 2 mM 3-D-phosphoglyceric acid, and 1 µM 
MoeO5. Pyrophosphates tested were geranyl, farnesyl, geranylgeranyl, and 
moenocinyl pyrophosphate. Reactions were initiated with the addition of 40 µM 
of isoprenoid pyrophosphate. The reactions were incubated for 1 h at 37°C and 
quenched with an equal volume of methanol. The quenched reactions were 
centrifuged (5 min at 10,000g) to remove precipitated protein. Reactions were 
analyzed on an Agilent 1200 LC/MS (conditions described above) with a linear 
gradient over 10 min. For the farnesyl pyrophosphate reaction, no detectable FPP 
starting material was observed following a 1 h incubation. Reactions were 
performed with MoeO5 purified from S. lividans and with Sumo-MoeO5 purified 
from E. coli, and the results were identical. 
For NMR analysis, compound 7 was scaled up and purified by C18 
column (Extract-Clean SPE C18 column (Alltech), eluted in methanol) followed 
by preparative TLC (solvent system: 6:4:0.85 chloroform/methanol/water, run and 
dried three times). 1H resonances for compound 7 were assigned from one-
dimensional (1D) and two-dimensional (2D) COSY spectra based on reported 
data. Multiplicities are reported by using the following abbreviations: s = singlet, 
d = doublet, t = triplet, m = multiplet, and br = broad. δH (500 MHz, D2O) 1.618 
(s, 3H); 1.625 (s, 3H); 1.693 (s, 3H); 1.774 (s, 3H); 2.007-2.035 (m, 2H); 2.094-
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2.157 (m, 6H); 3.858 (br s, 1H); 3.956-4.038 (m, 3H); 4.126 (br s, 1H); 5.181 (br 
s, 2H); 5.415 (s, 1H). The stereochemistry of the allylic bond was confirmed to be 
cis based on 1D NOESYs. 
 
Characterization of MoeE5. Reconstitution of MoeE5 activity was performed in 
reactions containing 20 mM Tris-HCl at pH 7.5 and 1 mM UDP-GlcUA. The 
reactions were initiated by the addition of 1 µM MoeE5, incubated at 37°C for 2 
h, and quenched by boiling for 5 min followed by centrifugation (5 min at 
10,000g) to remove precipitated protein. Reactions were analyzed by anion-
exchange HPLC (Phenomenex Phenosphere SAX 5 µm, 100 Å column, 250 mm 
4.6 mm) on an Agilent 1100 HPLC over a 30 min salt gradient flow rate of 1 
mL/min (solvent A: 5 mM NH4H2PO4 at pH 4.5; solvent B: 750 mM NH4H2PO4 
at pH 3.7) (Frirdich et al, 2005). 
 
Characterization of MoeGT1. Reconstitution of MoeGT1 was carried out in 
reactions with 50 mM Tris-HCl at pH 7.5, 150 mM NaCl, 5 mM MgCl2, 1 mM 
UDP-sugar (UDP-GlcUA, UDP-GalUA, or an epimeric mixture of UDP-GlcUA 
and UDP- GalUA), and 40 µM 7. Reactions were initiated by the addition of 800 
nM MoeGT1, incubated at 37°C, quenched at specific time points by the addition 
of 1 volume methanol (see Figure 3.5 for time points), and centrifuged (5 min at 
10,000g) to remove precipitated protein. Reactions were analyzed on an Agilent 
6200 LCMS (conditions described above for MoeO5) with a linear gradient over 
10 min. Product and substrate peaks were integrated, normalized, and used to 
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calculate percent conversion in µmols. 
 
Generation of recombinant S. lividans and S. ghanaensis strains. Standard 
molecular biology procedures were used throughout the work (Kieser et al, 2000; 
Sambrook et al, 2001). For all λ-RED-assisted deletions of moe genes within 
cosmid moeno38-1 (except for moeGT3), the entire open reading frame was 
replaced with a kanamycin resistance cassette (pKD4). The mutated cosmid was 
introduced into strain DH5α (pCP20) to evict kanR as described (Datsenko et al, 
2000). Deletions within the cosmids were confirmed by PCR. To create the 
ΔmoeGT5ΔmoeGT3 strain, λ-RED recombination was used to replace moeGT3 
with the disrupted allele moeGT3::aadA in the ΔmoeGT5 derivative of moeno38-
1. All constructs were transferred into S. lividans via intergeneric conjugation. 
Integration of moeno38-1 and its derivatives into the S. lividans genome was 
confirmed as described (Ostash et al, 2007). Gene moeGT3 was insertionally 
inactivated in the S. ghanaensis genome according to an established procedure 
(Ostash et al, 2007). Plasmid borne copies of the genes were used to complement 
the gene deletions. 
 
Moenomycin production and analysis. Small-scale fermentation and purification 
of moenomycins was performed as described previously (Ostash et al, 2007). To 
obtain pure moenomycin intermediates (>90% as judged by TLC) from 
recombinant S. lividans strains, the following procedure was used. TSB medium 
(30 mL) in a 250 mL flask containing 70 glass beads (5 mm) was inoculated with 
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100 µL (approximately 104-105 cfu) of stock culture (kept in 10.3% sucrose at -
20°C). The flask was incubated on an orbital shaker (240 rpm) for 2 days at 37°C 
and then used as a preculture to start the fermentation. Slightly modified R5 
medium (Kieser et al, 2000) (sucrose: 6% instead of 10.3%; 1 mg/L CoCl2 added 
after autoclaving) was used as a fermentation medium. Eight 4 L flasks (500 mL 
of medium per flask) containing beads were grown for 6 days at 37°C. Using the 
floor shaker in a warm room fixed at 37°C provided maximized aeration and 
optimized antibiotic production compared to smaller incubated shakers at 30°C. 
The mycelium was collected by centrifugation and extracted exhaustively with 
methanol-water (9:1) at 37°C (when necessary, the pH of the extraction mixture 
was adjusted to 7 - 7.5 with Tris-HCl). The extract was concentrated, 
reconstituted in water, and extracted with dichloromethane. The aqueous phase 
was loaded on a XAD-16 column (30x400 mm), washed with water (300 mL), 
and eluted with methanol (500 mL). Methanol fractions containing the desired 
compound were combined, concentrated and purified on a Sep-Pak C18 SPE 
cartridge (Waters) as described (Eichhorn et al, 2005). Further silica gel flash 
chromatography or preparative TLC of the extract was performed according to 
Adachi et al. (2006) and yielded pure compound (0.025-0.1 mg/L, depending on 
the strain). Antibiotic disk diffusion assays, LC-MS, MS/MS, and determination 
of accurate mass spectra of moenomycins were carried out as described 
previously (Ostash et al, 2007). MIC values (µg/mL) were obtained using a 
standard microdilution assay. The MIC is defined as the lowest antibiotic 
concentration that resulted in no visible growth after incubation at 37°C for 22 h. 
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1H NMR spectrum of compound 20 was recorded on a Varian Inova 500 (500 
MHz) instrument in D2O (4.80 ppm). 
 
3.3: Results 
Description of the approach. The MmA biosynthetic genes are located in two 
clusters on the S. ghanaensis chromosome: a three gene operon involved in A ring 
assembly (moe cluster 2) and a larger cluster containing the genes involved in the 
assembly of the phosphoglycolipid pentasaccharide scaffold (moe cluster 1) 
(Adachi et al, 2006; Taylor et al, 2006; Ostash et al, 2007). We have now 
reconstituted the biosynthesis of MmA in S. lividans using a three-component 
heterologous expression system. The three components include the previously 
described integrative cosmid moeno38-1, which contains all but two of the genes 
of moe cluster 1, the replicative plasmid pOOB49f, which supplies the two 
missing moe cluster 1 genes, and the integrative plasmid pOOB64b, which 
contains the three genes in moe cluster 2 (Figure 3.2) (Ostash et al, 2007). To 
probe the functions of the putative biosynthetic genes, we have constructed a 
series of derivatives carrying λ-RED-induced single or double gene deletions in 
cosmid 38-1 or other components of the heterologous expression system (Table 
3.1) and have prepared recombinant S. lividans strains expressing the subsets of 
genes. One gene deletion (moeGT3) was prepared in the producing organism, S. 
ghanaensis. We then analyzed the phosphoglycolipids produced by the resulting 
strains. Because production levels in the heterologous host are low, we made use 
of exact mass data and previously established fragmentation patterns of the 
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moenomycins to assign structures. MS2 fragmentation patterns of 
phosphoglycolipids from fermentation have been extremely well characterized by 
both Eichhorn et al. (2005) and Zehl et al. (2006), allowing us to confirm the 
structures of our compounds. One example is shown in Figure 3.3. Proton NMR 
spectra were used to confirm assignments in cases, in which sufficient material 
was obtained (compounds 7 and 20). To address polar effects, deletion strains 
were complemented with plasmid-borne copies of the genes. When genetic 
approaches could not reveal function (with MoeO5, MoeGT1, and MoeE5), we 
used biochemical reconstitution of enzymatic activity in vitro to establish 
substrates and products. 
 
 
 
Figure 3.2: Moe clusters 1 & 2. Three parental DNA constructs were used to 
generate all other recombinant cosmids and plasmids described in this study. 
Cosmid moeno38-1 carries all of moe cluster 1 except moeR5moeS5. Plasmid 
pOOB49f carries moeR5moeS5 under the control of the ermE promoter. The three 
genes in moe cluster 2 are carried on plasmid pOOB64b. 
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Table 3.1: Data for phosphoglycolipids from recombinant strains and in vitro 
reconstitution 
 
m/z [M - H]- 
Source   Compound Retention time (min)  Calculated  Observed 
 
38-1+ΔmoeA5ΔB5  3   9.9b    1500.6273  1500.6272 
38-1+ΔmoeF5  8   3.9b    565.2050  565.2055 
38-1+ΔmoeGT4  9a  4.7b    564.2210  564.2221 
38-1+ΔmoeGT5ΔGT3  11  4.8b    781.3160  781.3147 
38-1+ΔmoeGT5  20  10.4b    1122.4998  1122.5005 
38-1+ΔmoeGT2  22  10b    1325.5792  1325.5786 
38-1+moeR5+ΔmoeH5  23  9.4b    1485.6164  1485.6199 
38-1+ΔmoeH5  24  9.3b    1501.6113  1501.6113 
38-1+pBOO64b+ΔmoeH5 24  9.3b    1501.6113  1501.6139 
38-1+moeR5+ΔmoeA5ΔB5 25 10b    1484.6324  1484.6329 
38-1+pBOO64b+ΔmoeA5ΔB5 2  9.3b    1596.6490  1596.6439 
38-1+ΔmoeK5  4   9.6b    1486.6116  1486.6118 
38-1+ΔmoeN5  5   4.1b    1365.4861  1365.4867 
 6   4.2b    1364.5021  1364.5023 
S. ghanaensis MO12  26d  9.2b    1418.6007  1418.6016 
 
MoeO5 in vitro  7   6.5c    389.1729  389.1737 
MoeE5 in vitro  UDP-GalUA  5.6    579.2793  579.279 
 UDP-GlcUA  16.0 
MoeGT1 in vitro  8   6.6c    565.2050  565.2066 
 
aThe C4 equatorial epimer of 9 cannot be excluded, but it is not consistent with the reported 
desmethyl MmA analogue obtained via fermentation nor with evidence that UDP-GalUA is the F 
ring sugar donor. bColumn: 250 x 4.6mm Agilent C18 column; conditions are as previously 
reported (Ostash et al, 2007). cColumn: 100 x 4.6 mm Gemini C18 column; HPLC conditions are 
described in Materials and Methods.  
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Figure 3.3: Fragmentation patters of moenomycin A. Observed fragmentation 
patterns of (a) moenomycin A (m/z observed, 1580.6430; calculated, 1580.6535) 
and (b) compound 5 (m/z observed, 1364.5023; calcd, 1364.5021), which lacks 
the C5Nunit (A ring), contains farnesyl (C15) rather than moenocinyl (C25) lipid, 
and has a GlcNAc rather than a chinovosamine C ring for a mass difference of 
217. The fragment ions observed for moenomycin A are assigned on the basis of 
published data by Eichorn et al. (2005). The corresponding fragment ions are 
observed for compound 5.  
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Functions of the prenyltransferases MoeO5 and MoeN5. Moenomycin contains an 
irregular isoprenoid chain attached via a cis-allylic ether linkage to 
phosphoglycerate. On the basis of in silico analysis of moe cluster 1, we 
previously proposed that moeO5 and moeN5, two putative prenyl transferases, are 
involved in the assembly of the moenocinyl chain (Ostash et al, 2007). MoeO5 is 
a predicted TIM-barrel protein that shows homology to the prenyl transferases 
that transfer geranylgeranyl to glycerol phosphate in the first step of archael 
membrane lipid biosynthesis (Zhang et al, 1993; Payandeh et al, 2006). On the 
basis of this resemblance, we suggested that MoeO5 forms an ether linkage 
between D-3-phosphoglyceric acid and an activated moenocinyl chain (Ostash et 
al, 2007). To test this hypothesis, we cloned and expressed MoeO5 in both S. 
lividans and E. coli. After purification, MoeO5 was incubated at 37°C with 2 mM 
D-3-phosphoglyceric acid and 40 µM of moenocinyl pyrophosphate. No product 
was observed even after an overnight incubation. MoeO5 was then incubated with 
one of several commercially available prenyl pyrophosphates, including geranyl, 
farnesyl, and geranylgeranyl pyrophosphate. MoeO5 completely converted 
farnesyl pyrophosphate to compound 7 within 1 h. The product was purified and 
shown by NMR to contain a cis-allylic ether bond like the natural product (Figure 
3.4, Table 3.1). It is worth noting that double bond isomerization, although 
common in prenyl cyclase reactions, has not previously been observed for a 
prenyl transferase that catalyzes an intermolecular coupling (Dewick, 2002; Liang 
et al, 2002; Domingo et al, 2009). Furthermore, it does not occur in the reactions 
catalyzed by the archaeal homologues of MoeO5  (Zhang et al, 1993; Payandeh et 
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al, 2006). This and other differences in the substrates and products of the archaeal 
enzymes compared with MoeO5 suggest that TIM-barrel prenyl transferases, a 
largely unexplored family of enzymes, may display considerable variability in the 
types of reactions they catalyze (Wierenga, 2001; Nagano et al, 2002; 
Anantharaman et al, 2003; Caetano-Anolles et al, 2009). 
Since MoeO5 generates a C15 lipid-phosphoglycerate while MmA 
contains a C25 lipid, we surmised that the other prenyltransferase, MoeN5, must 
couple the C10 lipid from a pyrophosphate donor to a z-farnesylated intermediate 
in the biosynthetic pathway. Efforts to reconstitute the activity of MoeN5 using 
starter unit 7 and geranyl pyrophosphate as substrates were unsuccessful. 
However, we found that strain 38-1+ΔmoeN5 accumulates compounds 5 and 6, 
which contain farnesyl instead of moenocinyl moieties (Figure 3.1b and Table 
3.1). Isolation of 5 and 6 from the 38-1+ΔmoeN5 strain confirms that MoeN5 
catalyzes C10 prenyl transfer, presumably using geranyl pyrophosphate from 
primary metabolism as a substrate. A mechanism for the unusual rearrangement 
that produces the moenocinyl chain was proposed by Arigoni, Welzel, and co-
workers (Neundorf et al, 2003), and this mechanism is consistent with the finding 
that the C25 chain is constructed via C10 prenyl transfer to a C15-containing 
intermediate. In cells, MoeN5 apparently only acts on glycosylated intermediates 
(see below), a finding that may explain our inability to reconstitute its activity 
using 7 as a substrate. 
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Figure 3.4: Proposed pathway for moenomycin biosynthesis. Solid arrows 
indicate the order of moenomycin assembly. Structural components shown in red, 
green, and blue indicate the positions of new moieties in the biosynthetic 
intermediates. Asterisks (*) indicate biologically active compounds. Structures 
shown are consistent with exact mass and MS2 fragmentation data. 
Stereochemical assignments are consistent with the extensive body of literature on 
moenomycins isolated from fermentation broths (Donnerstag et al, 1996; Hennig 
et al, 1998). We cannot exclude the possibility that the tailoring enzymes are able 
to act at multiple points during assembly. 
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Functions of the glycosyltransferases. To probe the functions of each of the five 
putative glycosyltransferase genes in moe cluster 1, we disrupted each of them 
either singly or in combination (Figure 3.2). We were able to isolate glycosylated 
MmA intermediates from strains deficient in MoeGT2, MoeGT3, MoeGT4, and 
MoeGT5, but not from a strain deficient in MoeGT1. Taken together, these results 
suggested that MoeGT1 transfers the first sugar to the lipid phosphoglycerate. 
Based on the structure of the F ring, we speculated that the natural substrate for 
MoeGT1 is either UDP-glucuronic acid (UDP-GlcUA) or UDP-galacturonic acid 
(UDP-GalUA). To verify the function of MoeGT1 and assess its donor sugar 
substrate specificity, we cloned and overexpressed the enzyme as a His-tag fusion 
in E. coli. Following purification, MoeGT1 was incubated with 40 µM of farnesyl 
phosphoglycerate 7 and 1 mM of either UDP-GlcUA or a mixture of UDP-GlcUA 
and UDP-GalUA, prepared by incubating UDP-GlcUA with a well-characterized 
UDP-GalUA C4-epimerase from Klebsiella pneumoniae, GlaKP (Frirdich et al, 
2005). After 2 h, a product having an exact mass corresponding to compound 8 
was detected in both reactions; however, the epimeric mixture of sugars reacted to 
>80% completion while pure UDP-GlcUA only went to 10% completion (Table 
3.1). Although Michaelis-Menten analysis of MoeGT1 is currently hampered by 
the low activity of the reconstituted enzyme, a comparison of the two sugar 
donors following separation of the epimeric mixture showed a clear preference for 
UDP-GalUA over UDP-GlcUA (0.34 µmol/min for UDP-GalUA and 0.08 
µmol/min for UDP-GlcUA, Figure 3.5). Therefore, UDP-GalUA is assigned as 
the natural sugar for MoeGT1, consistent with the presence, demonstrated below, 
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of a UDP-GalUA C4 epimerase in moe cluster 1. 
 
 
Figure 3.5: Kinetics of MoeGT1. Comparison of the MoeGT1 reaction carried 
out at 37 °C in 50 mM Tris-HCl at pH 7.5, 150 mM NaCl, 5 mM MgCl2, 40 µM 
compound 7, 800 nM MoeGT1, and 1 mM of either UDP-GlcUA (•) or UDP-
GalUA (♦).  
 
 
The functions of the other glycosyltransferases were established by analyzing 
MmA intermediates produced by various gene disruption strains. The 
recombinant 38-1+ΔmoeGT4 strain was found to accumulate monosaccharide 9 
(Figure 3.4), suggesting that it attaches the E ring sugar. Consistent with this 
assignment, all strains containing disruptions of moeGT5, moeGT2, and moeGT3, 
either individually or in combination, were found to produce moenomycin 
precursors containing the E ring (Figure 3.4 and Table 3.1). Furthermore, 
complementation of the deletion strain with a plasmid-borne copy of moeGT4 
produced the desmethylated pentasaccharide 4. On the basis of these results, we 
conclude that MoeGT4 acts after MoeGT1 to produce the C15 disaccharide 11. 
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Upon complementation of the 38-1+ΔmoeGT4 strain, desmethyl compound 4 was 
produced rather than 3 because the 3’ end of the putative methyltransferase 
moeK5 gene overlaps with moeGT4. Although the moeGT4 gene deletion affected 
the expression of moeK5, the functional assignments of these genes are not 
affected (see below; see also Figures 3.2 and 3.4). 
The order of biosynthesis with respect to the remaining three 
glycosyltransferases, MoeGT2, MoeGT3, and MoeGT5, indicates a branching 
pathway. Strains 38-1+ΔmoeGT5 and 38-1+ΔmoeGT2 were found to produce 
trisaccharide 20 (Figure 3.4) and tetrasaccharide 22 (Figure 3.4), respectively. 
However, the double mutant strain 38-1+ΔmoeGT5ΔmoeGT3 accumulated C15 
disaccharide 11 (Figure 3.4 and Table 3.1). Moenomycin analogues lacking the 
branching glucose (the D ring) are naturally produced in S. ghanaensis (Welzel, 
2005). We found that they also accumulate when moeGT3 is disrupted in the 
producing organism (S. ghanaensis MO12, Table 3.1). Therefore, we propose that 
MmA biosynthesis can follow two branches from 11, depicted in Figure 3.4, 
which merge at the stage of the tetrasaccharide 21/22. In one branch, MoeGT5 
attaches the C ring, which can be either chinovosamine (Ch) or N-
acetylglucosamine (GlcNAc), depending on the presence of moeR5moeS5 (see 
below) before MoeGT3 attaches the D ring. In the other branch, MoeGT3 attaches 
the D ring glucose before MoeGT5 attaches the C ring. MoeN5 then extends the 
lipid chain on trisaccharides 14/15 and 19 to produce 16/17 and 20. The absence 
of mono- and disaccharide phosphoglycolipids having the full lipid chain suggests 
that the moenocinyl chain is assembled in two distinct phases, although the reason 
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for this unusual order of assembly is unclear. Following chain elongation, F ring 
tailoring (see below), and attachment of the fourth sugar (by either MoeGT5 or 
MoeGT3 depending on which acted previously), MoeGT2 attaches the B ring 
sugar to produce the pentasaccharide precursors 23/24 (Figure 3.4). 
 
Functions of the sugar biosynthesis enzymes. While the gene clusters for most 
carbohydrate-containing secondary metabolites contain numerous genes involved 
in the synthesis of nucleotide-sugar building blocks, there are only three genes in 
the moe cluster that appear to be involved in producing NDP-sugar donors. 
Apparently, the nucleotide-sugar building blocks for moenomycin are siphoned 
directly from primary metabolism and used largely without further modification. 
The three sugar biosynthetic genes identified in the moe cluster are moeE5, which 
encodes a putative nucleotide sugar epimerase, and moeR5-moeS5, which encode 
a 4,6-dehydratase/keto-reductase pair. To evaluate the function of these three 
putative NDP-sugar biosynthetic genes, we constructed the appropriate 
recombinant strains. 
The 38-1+ strain, which is lacking moeR5moeS5, accumulates MmA 
derivative 3 containing GlcNAc in place of chinovosamine (C ring, Figure 3.1), 
implying that the missing genes control the conversion of UDP-GlcNAc to UDP-
chinovosamine (UDP-Ch, Figure 3.4). Consistent with this notion, we found that 
supplying the missing genes on a plasmid produces a strain, 38-1+moeR5+-
moeS5+, which accumulates a compound (25) (Figure 3.4 and Table 3.1) 
containing a methyl at C6 of the C ring. Further studies showed that a 38-
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1+moeS5+ strain yielded only the hydroxy-methyl variant 3 (Ostash et al, 2007); 
however, a 38-1+moeR5+ strain produced 25 in addition to 3. It is possible that a 
homologue of moeS5 in the S. lividans genome complements the loss of moeS5 
function in the 38-1+moeR5+ strain. Alternatively, MoeR5 may contain both 
ketoreductase and dehydratase activities. In any event, these results show that 
moeR5 is required for the biosynthesis of UDP-chinovosamine, the C ring donor 
for MmA biosynthesis, from UDP-GlcNAc. 
To determine the function of the putative nucleotide sugar epimerase 
moeE5, we constructed strain 38-1+ΔmoeE5, and analyzed its cell extracts. We 
were unable to detect any phosphoglycolipid compounds in these extracts. Since 
the apparent glycosyl donor substrate for MoeGT1 is UDP-GalUA (see above), 
we hypothesized that MoeE5 is responsible for epimerizing UDP-GlcUA obtained 
from primary metabolism to UDP-GalUA. To test this hypothesis, we cloned and 
expressed MoeE5 as a His-tagged fusion in E. coli. MoeE5 was incubated with 
UDP-GlcUA, and the nucleotide-sugar products were then analyzed by anion-
exchange HPLC. Pure UDP-GlcUA and the epimeric mixture produced by GlaKP, 
a well-characterized UDP-GalUA C4-epimerase from K. pneumoniae, were used 
as authentic standards (Frirdich et al, 2005). MoeE5 was found to convert UDP-
GlcUA to a 60:40 mixture of compounds having the same exact mass and 
identical retention times as those of the authentic standards (Figure 3.6). 
Therefore, we conclude that MoeE5 epimerizes UDP-GlcUA to UDP-GalUA to 
provide the first sugar in MmA biosynthesis. 
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Figure 3.6: HPLC of UDP-GlcUA and UDP-GalUA. Anion-exchange HPLC 
(see Materials and Methods for conditions) of commercial UDP-GlcUA (peak 3), 
GlaKP incubated for 2 h at 37 °C with 1 mM UDP-GlcUA in 20 mM Tris-HCl at 
pH 7.5, MoeE5 incubated for 2 h at 37 °C with 1 mM UDP-GlcUA in 20mM 
Tris-HCl at pH 7.5, and UDP-GalUA (peak 2) purified from the MoeE5 reaction. 
NAD+/NADH (peak 1) is strongly associated with both epimerases, and, although 
it is likely a necessary coenzyme, it was not necessary to add it exogenously. 
 
Functions of the sugar tailoring enzymes. Moe cluster 1 contains several genes 
proposed to encode tailoring enzymes that modify sugars on the growing 
phosphoglycolipid scaffold. These tailoring enzymes include two genes (moeA5 
and moeB5) that are truncated homologues of two of the three genes in moe 
cluster 2 (moeA4 and moeB4, Figure 3.2). The three genes in moe cluster 2 encode 
a putative aminolevulinate synthase (moeA4) as well as two other enzymes 
proposed to be involved in the assembly and attachment of the A ring. Deletion of 
moeA4 from moe cluster 2 in the producing organism abolishes A ring formation 
(Sung et al, 2009). Therefore, the putative aminolevulinate synthase in moe 
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cluster 1, moeA5, cannot complement the loss of moeA4 and is likely 
nonfunctional. Expression of moe cluster 2 in the 38-1+ΔmoeA5ΔmoeB5 deletion 
strain produces analogues containing the A ring. These observations indicate that 
moe cluster 2 is required for A ring assembly. Neither moeA5 nor moeB5 of moe 
cluster 1 is required for MmA biosynthesis. 
The remaining putative tailoring enzymes in moe cluster 1 include moeF5, 
moeH5, moeK5, and moeM5. MoeF5 and moeH5 both encode amidotransferases 
proposed to form primary amides from carboxylic acids. However, MmA contains 
only one unsubstituted amide (on the F ring), which led us to propose previously 
that MoeF5 and MoeH5 may work together to catalyze amidotransfer, although 
we also considered the possibility that only one of the genes was functional. To 
probe whether both genes are required for MmA biosynthesis, we disrupted each 
one individually. Strain 38-1+ΔmoeF5 accumulated monosaccharide 8, which has 
a carboxyl moiety at C6 instead of a carboxamide group (Figure 3.4 and Table 
3.1). No methylated monosaccharide precursors or larger phosphoglycolipids 
could be detected. These results imply that MoeF5 is necessary for F ring 
carboxamidation and imply that the absence of the carboxamide moiety abolishes 
unit F methylation and all subsequent transformations. 
Strain 38-1+ΔmoeH5 accumulated phosphoglycolipid 24 (Figure 3.4 and 
Table 3.1), indicating that MoeH5 catalyzes carboxamidation of the C6 position 
of the B ring. This finding may explain the observation that C6 B ring primary 
amides and acids are observed in addition to MmA in fermentations of 
moenomycins (see Figure 3.1) (Eichhorn et al, 2005; Zehl et al, 2006). Several 
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other secondary metabolites contain C5N units identical to the A ring of MmA, 
and it has been proposed that these subunits are attached in a process involving 
attack of an amine on an activated acid to form the corresponding amide (Cho et 
al, 1993; Hu et al, 2004; McAlpine et al, 2005; Ostash et al, 2007). Since an 
activated acid is a putative precursor in the biosynthesis of MmA, we wondered 
whether B ring amides are intermediates in the MmA pathway or belong to a 
different branch of moenomycin metabolism. To determine whether the MoeH5 
reaction catalyzes an essential biosynthetic step required for attachment of the 
unit A chromophore, we coexpressed the genes for unit A biosynthesis 
(pOOB64b) in strain 38-1+, which produces 3 in the absence of the A ring genes, 
and also in strain 38-1+ΔmoeH5, which produces 24 in the absence of the A ring 
genes (Figure 3.4). We observed that pholipomycin 2 (Figure 3.1b), which 
contains the A ring, accumulates in the 38-1+pOOB64b+ strain but not in the 38-
1+ΔmoeH5pOOB64b+ strain (Table 3.1) (Welzel, 2005). The inability of the 
strain deficient in MoeH5 to make a product containing the A ring implies that 
carboxylic acid 24 is not the direct precursor to 2 (Schuricht et al, 2000; Petricek 
et al, 2006; Ostash et al, 2007). We propose that MoeH5 catalyzes the formation 
of carboxamides 3/25 as necessary precursors to MmA and pholipomycin, 
respectively (compounds 1 and 2, Figure 3.4). The details of the chemistry 
involved are not understood, but evidently do not involve attack of an amine on 
an activated acid. These results may have implications for the biosynthesis of 
other secondary metabolites containing C5N subunits. 
Gene moeK5 encodes a protein homologous to a recently discovered 
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family of putative radical-SAM, methyl-cobalamin-dependent methyltransferases 
involved in the biosynthesis of fosfomycin, pactamycin, and a handful of other 
secondary metabolites (Kuzuyama et al, 1992; Hidaka et al, 1995; Kuzuyama et 
al, 1995; Nunez et al, 2003; Unwin et al, 2004; Kudo et al, 2007; Woodyer et al, 
2007). We have proposed that MoeK5 controls the methylation of the first sugar 
(unit F) (Ostash et al, 2007). Indeed, strain 38-1+ΔmoeK5 accumulates the 
desmethylated MmA derivative 4 (Table 3.1 and Figure 3.1b). Since previous 
studies have shown that desmethyl MmA derivatives have the axial 
stereochemistry at C4 of the F ring (El-Abadla et al, 1999; Eichhorn et al, 2005), 
as shown in compound 4 (and consistent with our results showing that UDP-
GalUA is the F ring precursor), MoeK5-catalyzed methylation must proceed with 
inversion at the C4 hydroxyl. Because we identified methylated C15-
monosaccharide-phosphoglycerate compounds in extracts of several 
glycosyltransferase deletion strains, we have concluded that methylation of the F 
ring sugar occurs at the monosaccharide stage. It must occur following MoeF5-
catalyzed carboxamidation of the F ring since only desmethylated compound 8 
could be detected in the 38-1+ΔmoeF5 strain (Figure 3.4 and Table 3.1). 
The remaining tailoring enzyme, MoeM5, was established in our previous 
study to be a carbamoyltransferase since extracts from a S. ghanaensis strain in 
which the moeM5 gene was deleted produced only an inactive phosphoglycolipid 
pentasaccharide lacking the F ring carbamate (see Figure 3.1a) (Ostash et al, 
2007). However, the previous study provided no information on when MoeM5 
acts in MmA biosynthesis. We analyzed extracts from the set of moeM5+ 
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glycosyltransferase deletion strains produced in this study (see Table 3.1) to try 
and determine when the carbamate is installed. We detected only 
descarbamoylated products in extracts accumulating disaccharides; however, only 
carbamoylated products were detected in extracts accumulating trisaccharides and 
larger scaffolds. Therefore, we have concluded that carbamoylation occurs 
primarily at the trisaccharide stage during fermentation (Figure 3.4). This 
modification, however, is not required to complete the synthesis of the 
pentasaccharide scaffold since full-length analogues lacking the carbamate are 
produced in the ΔmoeM5 strain. 
On the basis of the preceding studies, we have concluded that moe cluster 
1 contains 14 demonstrably functional biosynthetic genes, while moe cluster 2 
contains 3. As described below, fewer than half of these 17 biosynthetic genes are 
required to produce bioactive MmA analogues, an observation that should 
facilitate efforts to produce novel analogues by pathway engineering. 
 
Antibacterial activity of moenomycins produced in recombinant strains. In order 
to define the subsets of genes required to make bioactive MmA analogues, we 
assessed the activity of phosphoglycolipids isolated from selected recombinant S. 
lividans strains on a Bacillus cereus reporter strain using a disk diffusion assay. 
Relative compound potencies were assessed by comparing the antibiotic 
concentrations required to achieve clear zones of inhibition. The results (Figure 
3.7 and Table 3.2) confirm previous structure-activity relationships reported by 
Welzel and others but also provide additional insights (Welzel et al, 1987; Welzel, 
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2005). As expected, monosaccharide compounds 8 and 9 were found to be 
inactive, while moenocinyl-linked tetra- and pentasaccharides 22 and 3 were 
found to have activity similar to that of MmA itself. These results confirm the 
modest role of the A ring in antibiotic activity. The C ring sugar was previously 
proposed to be an essential part of the minimal pharmacophore, but we have 
found that DEF trisaccharide 20 also has activity (Welzel, 2005). In fact, the MIC 
of 20 against a methicillin sensitive Staphylococcus aureus strain was found to be 
comparable to that of the CEF trisaccharide (8 µg/mL for 20 versus 3 µg/mL for a 
CEF trisaccharide analogue) (Welzel et al, 1987; Ritzeler et al, 1997; Welzel, 
2005; Adachi et al, 2006; Yuan et al, 2008). The observation that both 
trisaccharides have biological activity is consistent with structural work showing 
that the majority of directional contacts between moenomycin and its enzyme 
target involve only the EF-phosphoglycerate portion of the molecule, suggesting 
that this is the most critical portion of moenomycin for specificity (Yuan et al, 
2008; Heaslet et al, 2009; Sung et al, 2009). Since both trisaccharides are active, 
both could serve as starting points for the elaboration of phosphoglycolipid 
analogues. 
Some of the compounds produced in our studies also provide information 
about the minimum length of the lipid required for biological activity. It was 
established previously that MmA analogues containing neryl (C10) chains are 
biologically inactive even though they have midnanomolar enzyme inhibitory 
potencies (Adachi et al, 2006). This and other work have indicated an important 
role for the lipid chain in biological activity (Lovering et al, 2007; Lovering et al, 
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2008; Yuan et al, 2008; Heaslet et al, 2009). It is presumed that the prenyl chain 
must be long enough to interact with the cell membrane when the pentasaccharide 
scaffold is bound in the PGT active site so that it can compete with the lipid-
anchored substrates, which contain a C55 prenyl chain. We have found that 
farnesylated compounds 5 and 6, produced by deleting moeN5, show clear zones 
of inhibition. Therefore, three isoprene units in the prenyl chain are necessary and 
sufficient to confer biological activity, albeit with a loss in potency. The C25 
chain is believed to be responsible for many of the undesirable properties of 
MmA, including its excessively long half-life and propensity to bind serum. 
Biologically active analogues containing shorter lipid chains as well as other 
modifications to improve potency may have more favorable properties than MmA 
itself, and the studies reported here indicate that it should be possible to reduce 
the size of the lipid considerably. 
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Figure 3.7: Disk diffusion assay of MmA intermediates against reporter 
strain B. cereus ATCC19637. Disks 1 and 2, MmA (1), 10 and 100 nmol, 
respectively; disk 3, compound 22, 100 nmol; disk 4, compound 25, 100 nmol; 
disk 5, compound 23, 100 nmol; disk 6, compound 4, 100 nmol; disk 7, mixture 
of compounds 5 and 6, 200 nmol; disk 8, compound 20, 100 nmol; disk 9, mixture 
of compounds 4 and 5, 50 nmol; disk 10, extract from 5 g of S. lividans TK24 
mycelial cake; disk 11 compound 9, 200 nmol; disk 12, compound 8, 200 nmol. 
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Table 3.2: Relative antibiotic activity of MmA intermediates based on disc 
diffusion 
 
Compound       Antibiotic activitya 
 
1        +++ 
2        +++ 
3        +++ 
4        +++ 
5 and 6       + 
7        - 
8        - 
9        - 
11        - 
20        ++ 
22        +++ 
23        +++ 
24        +++ 
25        +++ 
 
a+++ indicates at least 90% as active as MmA, ++ indicates 50-89% activity, + 
indicates 15-49% activity, and - indicates no visible bioactivity. 
 
 
 
3.4: Discussion 
Summary of the biosynthetic pathway and implications for analogue production. 
The phosphoglycolipids, which target the active site of peptidoglycan 
glycosyltransferases, remain the only known starting points for the production of 
potentially useful antibiotics that target these enzymes. In this article, we have 
described a set of studies that have allowed us to propose a complete biosynthetic 
pathway for the synthesis of MmA, which should in turn enable the 
chemoenzymatic production of analogues. The pathway order is reconstructed 
from deletions of 17 moe genes and analysis/identification of accumulating 
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intermediates, bolstered by initial enzymatic assays of MoeO5, MoeGT1, and 
MoeE5. Biosynthesis begins with the coupling of farnesyl pyrophosphate and 
phosphoglycerate to form starter unit 7. Sugars are then sequentially attached by a 
series of glycosyltransferases, starting with the MoeGT1-catalyzed transfer of 
galacturonic acid (F ring precursor, Figure 3.4) to 7. Before additional processing 
can occur, the galacturonic acid must undergo an obligatory tailoring step by 
MoeF5, which converts the C6 carboxylic acid to a carboxamide. Methylation at 
the C4 position, catalyzed by MoeK5, then takes place but is not required for 
further biosynthetic steps to proceed. MoeGT4 transfers the second sugar, N-
acetylglucosamine (unit E, GlcNAc), to form the EF disaccharide. MoeGT5 and 
MoeGT3 then catalyze the addition of the C and D sugar units, respectively 
(Figure 3.4), but the order of addition is flexible. At the trisaccharide stage, 
MoeN5 catalyzes extension of the lipid chain to form the mature C25 isoprenoid 
chain, and MoeM5 catalyzes carbamoylation of the F ring. Neither modification is 
required for the other one to occur nor for subsequent glycosylations. After 
tetrasaccharide 21/22 is produced (by either MoeGT3 or MoeGT5), MoeGT2 
transfers another galacturonic acid subunit to the scaffold (B ring, Figure 3.4). 
The B ring C6 acid is then converted to the corresponding amide by MoeH5; this 
transformation is required for subsequent attachment of the C5N chromophore by 
the gene products encoded in moe cluster 2. 
The results described reveal considerable promiscuity in the moenomycin 
biosynthetic pathway, which may explain the observation that moenomycins are 
typically isolated as a complex mixture of related compounds (Schuricht et al, 
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2000; Zehl et al, 2006). We have found that except for unit F carboxamidation, 
every one of the sugar tailoring reactions can be bypassed without preventing the 
assembly of the phosphoglycolipid pentasacharide scaffold. Furthermore, both 
MoeGT4 and MoeGT5 can accept either UDP-GlcNAc or UDP-chinovosamine as 
donor substrates, explaining the production of pholipomycin (2) and moenomycin 
C3 as well as moenomycin A (1) in both producing organisms and the 
heterologous expression host (Welzel, 2005). The complexity of moenomycin 
mixtures obtained from fermentation has been a major hindrance to efforts to 
purify intermediates for various uses, including studies directed toward selective 
chemical derivatization to make novel phosphogycolipid analogues. It should now 
be possible to simplify the spectrum of moenomycin metabolites produced via 
fermentation or to optimize the production of new phosphoglycolipid scaffolds for 
chemoenzymatic synthesis by judicious deletion or overexpression of selected 
genes in either the producing organism or a suitable heterologous host (Schuricht 
et al, 2000). 
In addition to establishing gene function and the order of assembly of the 
pentasaccharide, we have identified the subsets of genes (7 out of the 17 total) 
required to form biologically active scaffolds. These genes include moeE5, 
moeO5, moeGT1, moeF5, moeGT4, moeM5, and either moeGT3 or moeGT5. It 
should be possible to produce phosphoglycolipid scaffolds for further chemical or 
enzymatic elaboration with 7 or fewer enzymes, depending on the exogenous 
substrates supplied, making in vitro reconstitution imminently feasible. The 
ability to reconstitute in vitro the production of small phosphoglycolipid scaffolds 
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will make it possible to explore the substrate tolerances of each enzyme in detail. 
This information should, in turn, be useful in guiding efforts to engineer 
heterologous hosts to produce novel phosphoglycolipid antibiotics or precursors 
for further chemical elaboration. 
 
3.5: Conclusions 
We have established functions for the 17 moenomycin biosynthetic genes, 
determined the order of assembly of the molecule, shown which transformations 
are required for full assembly of the pentasacharide scaffold, and identified the 
subsets of 7 genes involved in the production of bioactive analogues. This work 
will facilitate efforts to make analogues to explore the potential of 
phosphoglycolipids as useful antibiotics. 
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Chapter 4: Studies towards the reconstitution of the minimal pharmacophores 
of moenomycin A. 
 
4.1: Introduction 
The moenomycin  (MmA, 1, Figure 4.1) gene cluster has been identified in the 
producing organism Streptomyces ghanaensis (Ostash et al, 2007), and an order 
of assembly for MmA biosynthesis has been proposed using genetic analysis 
(Ostash et al, 2009). Evaluation of an MmA analog containing a C15-farnesyl 
lipid suggested that truncation of the C25-moenocinol lipid to a C15-farnesyl lipid 
maintains antibacterial activity. These studies also showed that C25-moenocinol 
trisaccharide scaffolds consisting of either the CEF or DEF rings are biologically 
active based on minimum inhibitory concentration (MIC) measurements. We also 
isolated a desmethyl-C25-moenocinol-pentasaccharide analog from a ΔmoeK5 
deletion strain to confirm that the 4’-methyl on glycan ring F is not required for 
biological activity (Ostash et al, 2009). The minimal MmA pharmacophore thus 
appears to be composed of the desmethyl-C15-farnesyl-CEF-trisaccharide 2a/b 
and/or the desmethyl-C15-farnesyl-DEF-trisaccharide 3a/b (Figure 4.1). 
Therefore, we set out to reconstitute the MmA enzymes that are required for the 
synthesis of these two putative minimal MmA pharmacophores (Figure 4.2). 
Successful reconstitution would allow verification of the proposed functions of 
the MmA enzymes that have not yet been verified, and also lay the groundwork 
for the exploration of substrate tolerance and the potential for the 
chemoenzymatic synthesis of MmA analogs. 
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Figure 4.1: MmA and trisaccharide pharmacophores. Chemical structures of 
moenomycin A (1), desmethyl-C15-farnesyl-CEF-trisaccharide (2), and 
desmethyl-C15-farnesyl-DEF-trisaccharide (3). 
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Figure 4.2: Enzymatic reconstitution scheme. Enzymatic synthesis of the 
putative MmA pharmacophores, desmethyl-C15-farnesyl-C, E, F-trisaccharide 
MmA (2a) and desmethyl-C15-farnesyl-D, E, F-trisaccharide MmA (3a). 
 
 
Reconstitution would allow the development of a chemoenzymatic method 
to assemble a MmA scaffold, which would then enable rapid exploration of the 
chemical space around the MmA pharmacophore. From a medicinal chemistry 
perspective, reconstitution is a cost-effective methodology for the development of 
a lead compound that has both the desired antibacterial and pharmacokinetic 
properties for further evaluation in animal models. Our strategy involved the 
chemical synthesis of unnatural substrates that probe the promiscuity of the 
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biosynthetic enzymes involved in assembling the MmA pharmacophore. 
Structure-activity relationship (SAR) data suggest that modifications to the lipid 
moiety as well as to select regions of the glycan rings C, E and F may result in 
analogs with enhanced biological activity (Halliday et al, 2006). We therefore 
focused our investigation on enabling modifications to the lipid and carbohydrate 
regions of MmA. We pursued two approaches: (1) the synthesis of unnatural 
phosphoglycerate lipid acceptors that would enable us to evaluate the range of 
lipid analogs that may be enzymatically attached to the carbohydrate portion, and 
(2) the synthesis of unnatural carbohydrate donors featuring functionalizable 
chemical handles that would enable us to evaluate the potential of assembling 
derivatizable MmA scaffolds. 
 
4.2: Results 
 
4.2.1: MoeF5 
Gene disruption studies indicated that MoeF5 is a putative amidotransferase 
necessary for the conversion of the F ring carboxylic acid 5 to the corresponding 
carboxyamide 6 (Ostash et al, 2009). These studies revealed that ΔmoeF5 S. 
lividans strains accumulate monosaccharide 5, suggesting that the absence of the 
carboxamide moiety abolishes downstream tailoring and glycosylation events. To 
verify the function of MoeF5, I reconstituted the activity of the protein. The 
protein was overexpressed in Rosetta2(DE3)pLysS E. coli cells, a strain 
optimized for the expression of high GC content proteins, and purified using Ni-
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NTA affinity chromatography (Figure 4.3). The identity of MoeF5 was confirmed 
by Western blotting using an antibody that recognizes the His6 tag. MoeF5 
consistently copurified with a slightly larger partner protein (asterix in Figure 
4.3). A second protein band just below MoeF5 on the SDS-PAGE gel could either 
be a degradation product or another protein that copurifies with MoeF5 
(arrowhead in Figure 4.3). Since MoeF5 has a theoretical isoelectric point of 9.4, 
cation exchange chromatography was tested to increase the purity of the sample, 
but the use of both strong (sulfate derivatives) and weak (carboxylic acid 
derivaties) cation exchange resins, was unsuccessful. Since the protein requires 
detergent (0.5% CHAPS) to remain soluble, it is possible that the contaminating 
proteins are chaperones or proteins that interact with the hydrophobic patches on 
MoeF5. Each liter of E. coli cells yielded approximately 0.2 mg MoeF5 protein.  
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Figure 4.3: SDS-PAGE gel of purified MoeF5. Lane 1: Molecular weight 
standards; lane 2: Ni-NTA affinity purified MoeF5. 
 
The function of MoeF5 was verified by incubating the protein with 40 µM 
C15-farnesyl-monosaccharide 5 and 10 mM glutamine in the presence of ATP. 
Liquid chromatography mass spectrometry (LCMS) of the product mixture 
revealed the appearance of product C15-farnesyl-F-amido-monosaccharide 6 after 
2 hours (Figure 4.4). The protein is also able to use ammonia (in the form of 
NH4OAc) as the nitrogen source. MoeF5 is indiscriminate towards Mg2+ and 
Mn2+ ions, but requires one or the other for activity, presumably to stabilize ATP 
in the catalytic cleft of the enzyme. MoeF5 also requires 10% DMSO, 10% 
glycerol, and 4 mM DTT in the buffer for efficient activity, as omission of any of 
these additives significantly reduced product turnover, which could then only be 
detected if a greater amount of starter material was used. 
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Figure 4.4: MoeF5 reaction: MoeF5 was incubated with 40 µM C15-farnesyl 
monosaccharide 5 and 10 mM glutamine in the presence of ATP. (a) The LCMS 
spectrum of the reaction after 2 h incubation reveals the presence of unreacted 
starting material 5. (b) The LCMS of the reaction after 2 h incubation reveals the 
presence of product C15-farnesyl-F-amido-monosaccharide 6. (c) Electron spray 
ionization mass spectrometry (ESI-MS) analysis of the starting material 5 peak: 
565.2056 [M−H]− calculated, 565.2 observed. (d) ESI-MS of product 6 peak: 
564.2215 [M−H]− calculated, 564.2 observed. 
 
 
4.2.2: MoeGT4 
Gene disruption studies indicated that MoeGT4 is a putative glycosyltransferase 
necessary for the coupling of the glycan ring E to the C15-farnesyl-F-amido-
monosacchride 6 (Ostash et al, 2009). To verify the function of MoeGT4, I 
reconstituted the activity of the protein. My initial constructs, N-terminally His-
tagged MoeGT4 (His6-MoeGT4) and C-terminally His-tagged MoeGT4 
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(MoeGT4-His6), expressed well but were insoluble, even in the presence of 
various ionic, non-ionic and zwitterionic detergents. A screen of ionic strength, 
pH, and the addition of divalent metal ions was also performed but unsuccessful. 
Hydropathy analysis of MoeGT4 in Expasy suggested that the protein contained a 
significant hydrophobic patch near its N terminus, which presumably anchors the 
protein to the periplasmic membrane in order to efficiently handle the lipophilic 
substrate and product molecules. I therefore constructed MoeGT4 with an N-
terminal thioredoxin tag (Trx-MoeGT4). This construct expressed well and was 
soluble in the presence of CHAPS (0.5%). Interestingly, Trx-MoeGT4 was 
extremely sensitive to salt (NaCl) and precipitated even in the presence of 50 mM 
NaCl. Ni-NTA affinity purified Trx-MoeGT4 is shown in Figure 4.5. Each liter of 
E. coli cells yielded approximately 2 mg MoeGT4. 
 
 
Figure 4.5: SDS-PAGE gel of purified MoeGT4. Lane 1: molecular weight 
standards; lane 2: Ni-NTA affinity purified Trx-MoeGT4. 
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The function of MoeGT4 was verified by incubating the enzyme with 
dried C15-farnesyl-F-amido-monosaccharide 6 and UDP-GlcNAc, and analyzing 
the reaction by LCMS (Figure 4.6). MoeGT4 was found to be active only in the 
presence of Mn2+, and addition of glycerol to the reaction buffer increased 
enzymatic catalytic activity. The Mn2+ cations are likely required to coordinate 
the diphosphate moiety of UDP-GlcNAc during catalysis.  
 
 
 
Figure 4.6: MoeGT4 reaction. MoeGT4 was incubated with dried C15-farnesyl 
F-amido monosaccharide 6 and UDP-GlcNAc in the presence of MnCl2. (a) The 
LCMS spectrum of the reaction after 10 h incubation reveals the presence of 
unreacted starting material 6. (b) The LCMS spectrum of the reaction after 10 h 
incubation reveals product C15-farnesyl-EF-disaccharide 7 formation. (c) ESI-MS 
analysis of the starting material 6 peak: 564.2215 [M−H]− calculated, 564.2 
observed. (d). ESI-MS analysis of the product 7 peak: 767.3009 [M−H]− 
calculated, 767.3 observed. 
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4.2.3: MoeGT5 
Gene disruption studies indicated that MoeGT5 is a putative glycosyltransferase 
necessary for the coupling of glycan ring C to the C15-farnesyl-EF 
monosacchride 7 (Ostash et al, 2009). To verify the glycosyltransferase activity of 
MoeGT5, I reconstituted the activity of the protein. MoeGT5 was difficult to 
express and purify. I first attempted to express MoeGT5 as either an N-terminally 
His-tagged protein (His6-MoeGT5) or a C-terminally His-tagged protein 
(MoeGT5-His6) in Rosetta2(DE3)pLysS E. coli cells, a strain that enhances the 
expression of high GC content genes. Unlike MoeGT1, MoeE5, MoeF5, and 
MoeGT4, which all exhibited higher soluble expression levels at 16°C as 
compared to 30°C or 37°C, MoeGT5 did not express at 16°C, even after an 
overnight incubation. MoeGT5 expressed at 37°C but exhibited unusual 
expression patterns. Expression levels peaked after 1 hour of induction with IPTG 
and steadily decreased to zero within 4 hours, presumably because the protein was 
degraded due to instability or misfolding. Expression of MoeGT5 in 
ArcticExpress E. coli cells, a strain that overexpresses chaperone proteins to 
enhance the folding and solubility of recombinant proteins, was, however, 
unsuccessful.  
Since the goal was to confirm its function rather than to produce large 
amounts of pure MoeGT5, I decided to obtain protein by using large quantities of 
cell mass harvested 1 hour after induction. After screening a panel of ionic, 
nonionic and zwitterionic detergents for their ability to extract MoeGT5 from the 
bacterial membranes, I found n-octyl-β-D-glucopyranoside (OG) to be the most 
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potent, enabling the extraction of ~30% MoeGT5. MoeGT5 copurified with many 
proteins on Ni-NTA affinity chromatography, and final yields of MoeGT5 were 
less than 0.2 mg per liter of culture.  
The function of MoeGT5 was probed by incubating the enzyme with dried 
C15-farnesyl-EF-disaccharide 7 and UDP-GlcNAc, and the reaction was analyzed 
by LCMS (Figure 4.7). Since only a small amount of starting material 7 could be 
obtained enzymatically, the amounts used for each MoeGT5 reaction were small 
(nM range). The limited starting material accounts for the appearance of multiple 
mass peaks at increasing elution times and the low ion count associated with the 
product 8 peak. Although the possibility remains that the peak associated with 
product represents noise rather than true product formation, the experiments were 
performed multiple times and the product 8 peak appeared reproducibly, 
suggesting that the enzyme was able to turnover substrate to product. For 
verification, the experiments need to be reproduced with more starting material 7.  
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Figure 4.7: MoeGT5 reaction. MoeGT5 was incubated with dried C15-farnesyl 
EF-amido disaccharide 7 and UDP-GlcNAc. (a) The LCMS spectrum of the 
reaction after 10 h incubation reveals the presence of unreacted starting material 
7. (b) The LCMS spectrum of the reaction after 10 h incubation reveals product 
C15-farnesyl-CEF-trisaccharide 8 formation. (c) ESI-MS analysis of the starting 
material 7 peak: 767.3009 [M−H]− calculated, 767.3 observed. (d) ESI-MS 
analysis of the product 8 peak: [M−H]− calculated, 970.4, 970.5 observed. 
 
 
4.2.4: MoeGT3 
Gene disruption studies indicated that MoeGT3 is a putative glycosyltransferase 
necessary for the coupling of the D ring to the C15-farnesyl-EF monosacchride 7 
(Ostash et al, 2009). To verify the function of MoeGT3, I tried to reconstitute the 
activity of the protein. Initial expression and solubilization attempts of N-
terminally His6-tagged MoeGT3 (His6-MoeGT3), C-terminally His6-tagged 
MoeGT3 (MoeGT3-His6), thiroedoxin-MoeGT3, and nus-MoeGT3 failed because 
all constructs formed insoluble inclusion bodies. Inclusion bodies formed with all 
combinations of expression conditions (temperature, late versus early induction, 
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amount of IPTG used), E. coli strains and detergents used. Since Streptomyces 
proteins are known to express poorly in E. coli, I also tried to express MoeGT3 in 
S. lividans. MoeGT3 expressed well in S. lividans, but was only soluble when 
clarification was performed at below 10,000g. A panel of ionic, nonionic, and 
zwitterionic detergents was assayed for their ability to increase the solubility of 
the protein. Although CHAPS and Triton-X100 were able to solubilize a small 
amount of MoeGT3, the protein yield was too low to test its function.  
 
4.2.5: MoeM5 
Gene disruption studies indicate that MoeM5 is a putative carbamoyltransferase 
that attaches a carbamate functionality on the F glycan ring after the assembly of 
either the C15-farnesyl-CEF trisaccharide or the C15-farnesyl-DEF trisaccharide 
(Ostash et al, 2009). IC50 measurements have indicated that the carbamoyl group 
increases the binding affinity of meonomycin to the peptidoglycan 
glycosyltransferases by 100 fold. I attempted to overexpress C-terminally His6-
tagged MoeM5 (MoeM5-His6), thioredoxin-MoeM5, and GST-MoeM5 in E. coli. 
All constructs formed insoluble inclusion bodies and the protein could not be 
refolded with detergent. In order to obtain soluble protein, I then attempted to 
express N-terminally His6-tagged MoeM5 and C-terminally His6-tagged MoeM5 
in S. lividans. Both constructs expressed well, remained soluble, and could be 
purified to near homogeneity in the presence of CHAPS or Triton X-100 (Figure 
4.8). Final yields approached 5 mg per liter of S. lividans culture. 
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Figure 4.8: SDS PAGE gel of purified MoeM5. Lane 1: Molecular weight 
standards; lane 2: Ni-NTA affinity purified His6-MoeM5; lane 3: Ni-NTA affinity 
purified MoeM5-His6. 
 
 
4.2.6: MoeGT4 substrate promiscuity 
Novel MmA analogs that contain amino sugars are excellent scaffolds that enable 
rapid chemical diversification. I synthesized UDP-3-amino-3-deoxy-GlcNAc via 
an enzymatic route established by Raetz and coworkers (2004) (Figure 4.9). A 
preliminary activity assay using MoeGT4 reaction conditions suggested that the 
enzyme was unable to recognize this amino sugar as a substrate. It may be that 
enzymatic turnover is low and that optimization of reaction conditions is needed 
enhance the turnover rate of the enzyme. 
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Figure 4.9: Enzymatic synthesis of UDP 3-amino-3-deoxy-GlcNAc. 
 
4.2.7: Synthesis of unnatural phosphoglycerate lipid acceptors 
The C25-moenocinol lipid of MmA contributes to the molecule’s poor 
pharmacokinetic properties. In collaboration with Dr. Hiro Tsukamoto, I 
synthesized 10 unnatural phosphoglycerate lipid acceptors that vary in length and 
structure (Figure 4.10). Since MoeGT1 displays substrate promiscuity towards the 
UDP-sugar donor, it is likely that the enzyme may also accept variations in the 
lipid acceptor, especially since the lipid is distant from the site of catalysis. This 
would enable the rapid synthesis of MmA analogs with diverse lipids that may 
exhibit better pharmacokinetic properties compared to the parent molecule.  
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Figure 4.10: A panel of chemically synthesized unnatural lipid acceptors to 
be tested as substrates for MoeGT1. 
 
 
4.3: Discussion  
This chapter describes efforts aimed at reconstituting the minimal moenomycin 
pharmacophores required for in vivo antibacterial activity. Initial expression and 
purification conditions have been worked out for MoeF5, MoeGT4, MoeGT5, and 
MoeM5. The purified proteins allowed the enzymatic activity of MoeF5, 
MoeGT4, and MoeGT5 to be verified. The activity of MoeM5 could not be 
ascertained, because of substrate material constraints. The expression and 
purification of MoeGT3 was attempted in E. coli and S. lividans, but in both cases 
it was not possible to isolate soluble protein. This problem was not anticipated, 
because the cellular conditions of S. lividans are similar to those of the producing 
organism, S. ghanaensis. Furthermore, since MmA could be isolated when the 
monomycin producing gene cluster was conjugated into S. lividans, MoeGT3 
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must be expressed in an active form in S. lividans. It is thus likely that expression 
parameters can be found that will allow soluble protein to be obtained. 
The reconstitution of glycosyltransferases MoeGT1, MoeGT4 and 
MoeGT5 enabled studies of their substrate promiscuity. Structural-activity 
relationship data suggest that modifications to the lipid moiety as well as to select 
regions of the glycan rings C, E and F may result in analogs with enhanced 
biological activity. Should the enzymes exhibit relaxed substrate specificity, a 
combination of two approaches can be used to generate a diverse array of 
moenomycin analogs: 1) Unnatural phosphoglycerate lipid acceptors can be 
synthesized to evaluate the range of lipid analogs that may be enzymatically 
attached by using MoeGT1, and 2) Unnatural carbohydrate donors can be 
synthesized with functionalizable chemical handles that enable chemical 
derivatization of the moenomycin scaffold. 
Unnatural lipids. The C25-moenocinyl lipid of moenomycin is believed to 
be responsible for the molecule’s undesirable pharmacokinetic properties (poor 
absorption, non-specific binding to cellular components) and inability to exhibit 
efficacy against gram-negative bacteria (Pfaller, 2006). The design of 
moenomycin analogs that overcome these limitations would be possible if 
MoeGT1 exhibits substrate promiscuity towards the acceptor lipid. The choice of 
unnatural lipid substrate should be motivated by the demands to 1) maintain or 
increase non-specific binding to the PGT active site as judged by IC50 
measurements and 2) maintain antibacterial activity while improving 
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pharmacokinetics as judged by measuring the differential in MICs in the presence 
and absence of serum.  
The semisynthesis of a C10-neryl moenomycin analog has shown that 
truncation of the C25-moenocinyl lipid to a C10-neryl lipid destroys antibacterial 
activity while exhibiting a negligible effect on peptidoglycan glycosyltransferase 
inhibition (Adachi et al, 2006). Recent studies suggest that a C15-farnesyl 
moenomycin analog isolated from genetically engineered S. lividans retains a 
similar level of antibacterial activity as moenomycin. It is likely that a certain 
amount of lipophilicity is required to target moenomycin to the membrane bound 
peptidoglycan glycosyltransferases. However, extensive lipophilicity, as on the 
parent molecule, contributes to non-specific binding to cellular components that 
results in a substantial reduction in the effective concentration of moenomycin. 
The currently available SAR data tentatively suggest that the C15-farnesyl lipid 
may represent the optimal isoprenyl lipid length required for antibacterial activity, 
and thus the panel of unnatural lipid substrates designed for MoeGT1 was based 
on this premise. It should be noted that MoeGT1 has predicted structural 
homology to MurG, a glycosyltransferase in peptidoglycan biosynthesis that 
exhibits remarkable acceptor lipid promiscuity. This similarity, together with the 
observation that the lipid is removed from the immediate site of catalysis, 
suggests that MoeGT1 has a high chance of exhibiting promiscuity.  
Unnatural sugars. Recent SAR data indicate that a trisaccharide 
configuration consisting of either the CEF or DEF glycan rings forms the smallest 
carbohydrate fragment that retains antibacterial activity (Ostash et al, 2009). 
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Although structural studies of a C10-neryl moenomycin analog bound to the A. 
aeolicus peptidoglycan glycosyltransferase suggest that the functionalities on the 
glycan rings E and F are critical in forming specific polar contacts with the 
enzyme, studies by Sofia and coworkers have shown that slight changes and 
additional derivatization with a range of chemical moieties may effect an increase 
in antibacterial activity (Sofia et al, 1999; Yuan et al, 2007). Detailed analysis of 
the crystal structure also suggests that there is space around the 3’-hydroxyl group 
of both the glycan rings C and E for addition of larger substituents to increase 
non-specific binding to the enzyme (Yuan et al, 2007). This finding provides 
compelling motivation to explore the possibility of introducing a chemical handle 
at the 3’ positions of the glycan rings C, E, and F to enable derivatization. 
The generation of a panel of C15-farnesyl-C/DEF-trisaccharide analogs 
containing 3-amino-3-deoxy modifications would enable rapid diversification of 
the moenomycin scaffold. Amines are attractive functionalities in drug design 
because they are charged at physiological conditions and nucleophilic and thus 
amenable to chemical derivatization. I synthesized UDP-3-amino-3-deoxy-
GlcNAc via an enzymatic route established by Sweet and coworkers (2004). 
Although an initial activity assay suggested that MoeGT4 is unable to utilize this 
UDP-amino sugar, this outcome could be due to unfavorable reaction conditions. 
More experiments are needed before definitive conclusions can be drawn. If 
conditions that induce MoeGT4 and MoeGT5 to accept unnatural UDP-amino 
sugars can be found, a diverse array of moenomycin derivatives can be made and 
tested for their antibacterial activities. Such derivatization could perhaps lead to 
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moenomycin analogs that exhibit high antibacterial acitivty and acceptable 
pharmacokinetic properties.  
 
4.4: Materials and methods 
Expression of Moe proteins. Plasmids encoding MoeGT1, MoeF5, MoeGT5, 
MoeE5, and MoeGT4 were transformed into Rosetta2(DE3)pLysS competent E. 
coli cells. Starting from a 10 mL overnight culture, MoeGT1, MoeF5, MoeE5, 
and MoeGT4 were grown at 37°C in Luria-Bertani (LB) medium to an OD600 of 
0.6. The temperature was reduced to 16°C and the cells were induced by the 
addition of 1 mM IPTG and allowed to grow overnight before harvesting by 
centrifugation. The overexpression plasmid for MoeGT5 was transformed into 
Rosetta2(DE3)pLysS competent E. coli cells and grown at 37°C in LB medium to 
an OD600 of 0.6. At that point, the cells were induced with 1 mM IPTG and grown 
for an additional 1 h before the culture was harvested by centrifugation. The 
overexpression plasmid for MoeM5, pJVD53-MoeM5, was conjugated into 
Streptomyces lividans. Starting from a 1 mL starter culture, MoeM5 was grown at 
30°C in YEME medium for 72 h before induction with e-caprolactam. The cells 
were then allowed to grow for an additional 24 h before harvesting by 
centrifugation.  
Purification of Moe proteins. Cell pellets containing MoeE5, MoeGT1, 
and MoeF5 were lysed by freeze-thaw in Buffer A (20 mM Tris-HCl, pH 8, 200 
mM NaCl, 5 mM imidazole, 5% glycerol, 0.5% CHAPS) supplemented with 
rlysozyme, benzonase, and protease inhibitor cocktail. Cellular debris and 
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membrane components were pelleted by centrifugation at 38,700 x g for 45 
minutes. The clarified cell lysate was loaded onto a column containing Ni-NTA 
resin equilibrated with Buffer A. The column was washed with 8 column volumes 
of Buffer W (20 mM Tris-HCl, pH 8, 200 mM NaCl, 5 mM imidazole) followed 
by 6 column volumes of Buffer W containing 30 mM imidazole. The proteins 
were eluted with a step gradient of imidazole in Buffer W (75-500 mM 
imidazole). Purified MoeE5 and MoeGT1 were dialyzed twice against 4 L of 20 
mM Tris-HCl, pH 7. Crudely purified MoeF5 was dialyzed twice against 3 L of 
20 mM Tris-HCl, pH 7, 4 mM dithiothreitol (DTT), and 10% glycerol.  
Cells from expression cultures of MoeGT4 were lysed by freeze-thaw in 
Buffer B (20 mM Tris-HCl, pH 8, 10% glycerol, 0.5% CHAPS) supplemented 
with rlysozyme, benzonase, and protease inhibitor cocktail. After centrifugation at 
16,000 x g for 40 min to remove cellular debris and membrane components, the 
supernatant was rocked with Ni-NTA resin for 6 h. The resin/lysate was loaded 
onto a column and washed with 18 column volumes of Buffer V (20 mM Tris-
HCl, pH 8, 5 mM imidazole) followed by 12 column volumes of Buffer V 
containing 30 mM imidazole. The purified protein was eluted with 500 mM 
imidazole in Buffer V, and dialyzed against 3 L of 20 mM Tris-HCl, pH 7, 5 mM 
MnCl2, and 10% glycerol.  
Cell pellets containing MoeGT5 were lysed by freeze-thaw in Buffer C 
(20 mM Tris-HCl, pH 8, 200 mM NaCl, 5 mM imidazole, 1% n-octyl-β-D-
glucopyranoside) supplemented with rlysozyme, benzonase, and protease 
inhibitor cocktail. After clarification of the cell lysate at 38,700 x g for 30 min, 
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the supernatant was loaded onto a column containing Ni-NTA resin. The protein 
was washed and eluted in a manner identical to the MoeGT1/MoeE5/MoeF5 
purification. 
Cell pellets containing MoeM5 were lysed in Buffer D (50 mM Tris-HCl, 
pH 7, 10% glycerol, 0.5% CHAPS or 0.5% Triton X-100) supplemented with 
rlysozyme and protease inhibitor cocktail. The protein was then clarified and 
purified in a manner identical to the MoeGT1/MoeE5/MoeF5 purification.  
C15-farnesyl-F-monosaccharide 5 biosynthesis. To synthesize C15-
farnesyl-F-monosaccharide 5, purified MoeGT1 was incubated with 0.1 mg C15-
farnesyl-phosphoglycerate 4 and 2 mM of a 3:2 mixture of UDP-galacturonic acid 
(UDP-GalUA) and UDP-glucuronic acid (UDP-GlcUA) at 30°C with mild 
shaking for 10 h. The reaction was stopped by passage through a Microcon 
filtration unit (10K molecular weight cut-off). Analytical HPLC was carried out 
on a Gemini C18 column (50 x 4.6 mm) using solvent A (95 water: 5 methanol + 
0.1% ammonium hydroxide) and solvent B (60 isopropanol: 35 methanol: 5 water 
+ 0.1% ammonium hydroxide). A gradient of 0-75% solvent B over 17 min was 
used at a flow rate of 1 ml/min. Product peaks were detected using absorbance at 
210 nm, collected, and characterized with high-resolution mass spectrometry: 
565.2056 [M−H]− calculated, 565.2066 observed. 
The C15-farnesyl-F-amido-monosaccharide 6 was synthesized by adding 
Buffer F (20 mM Tris-HCl, 4 mM DTT, 10% glycerol, 10% DMSO, 10 mM 
MgCl2, 10 mM ATP) to a tube containing dried C15-farnesyl-F-monosaccharide 5 
and glutamine, pH 9 (10 mM final concentration) or ammonium acetate, pH 7 
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(100 mM final concentration). The reaction was initiated by addition of crudely 
purified MoeF5, and allowed to incubate at 30°C with mild shaking for 10 h. The 
reaction was stopped by immersion into an 85°C water bath for 5 min followed by 
centrifugation at 14,000 x g for 10 min. Analytical HPLC was carried out as 
described above. Product peaks were detected using absorbance at 210 nm, 
collected, and characterized with ESI-MS: 564.2215 [M−H]− calculated, 564.2 
observed.  
To synthesize C15-farnesyl-EF-disaccharide 7, purified MoeGT4 was 
incubated with dried C15-farnesyl-F-amido-monosaccharide 6 and 5 mM UDP-
GlcNAc in Buffer 4 (20 mM Tris-HCl, pH 7, 10% glycerol, 5 mM MnCl2) at 
30°C with mild shaking for 10 h. The reaction was quenched and analyzed as 
described for the MoeGT1 reaction. The formation of product was detected with 
ESI-MS: 767.3009 [M−H]− calculated, 767.3 observed. 
To synthesize C15-farnesyl-CEF-trisaccharide 8, MoeGT5 was incubated 
with dried C15-farnesyl-E, F-disaccharide 7 and 5 mM UDP-GlcNAc in MoeGT4 
reaction buffer at 30°C with mild shaking for 10 h. The reaction was quenched 
and analyzed as described for the MoeGT1 reaction. The formation of product 
was detected with ESI-MS and HRMS.  
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Chapter 5: Introduction to RIG-I-like helicases  
 
5.1: The innate immune system 
Double-stranded RNA (dsRNA), the genetic material of many RNA viruses, 
triggers a powerful innate immune response in vertebrate organisms (Wang et al, 
2011). The innate immune response is rapid and coupled to adaptive immunity, 
which provides vertebrate organisms with long-term protection based on 
immunological memory (Rodriguez et al, 2012). The vertebrate immune system is 
able to distinguish between viral and host RNA. Characteristic viral components 
that are absent in the host organism include long dsRNA, 5’-triphosphorylated 
(ppp) RNA, and unmethylated CpG DNA (Zhong et al, 2010). Host mRNAs are 
typically capped and are bound by poly-A binding proteins (Afonina et al, 1998), 
and ribosomal RNAs are integrated into ribonucleoprotein complexes (Yusupov 
et al, 2001), thus providing the host organism protection from eliciting an 
autoimmune response. 
Effective immune defense against viral infection depends on the rapid and 
robust detection of pathogen-associated molecular patterns (PAMPs) by pattern 
recognition receptors. The innate immune system has developed two major 
pathways to respond to the detection of viral nucleic acids, each using a specific 
class of pattern recognition receptors. One pathway for the detection of viral RNA 
is mediated by Toll-like receptor 3 (TLR3), an integral membrane protein located 
in the endosome. TLR3 detects phagocytosed viral components that have been 
released into the extracellular space by infected cells that undergo lysis (Schulz et 
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al, 2005). TLR3 may also detect viruses that are internalized through receptor-
mediated endocytosis. When TLR3 is activated, it signals through the protein 
TIR-domain-containing adaptor-inducing interferon β (TRIF) to activate two 
kinases, TANK-binding kinase-1  (TBk1) and I-kappa B Kinase-epsilon (IKK-ε). 
These kinases phosphorylate interferon (IFN) transcription factors, which induce 
the expression of type-I IFNs (Hoebe et al, 2003; Yamamoto et al, 2003). 
The second pathway for the detection of viral RNA is mediated by the 
RIG-I-like receptors (RLRs), retinoic acid inducible gene-I (RIG-I) and 
melanoma differentiation-associated protein 5 (MDA5). RIG-I and MDA5 are 
conserved viral RNA receptors in vertebrates, sharing similar domain 
architectures and approximately 30% sequence identity (Wilkins et al, 2010). 
RLRs are expressed ubiquitously in most cell types and sense viral RNA in the 
cytoplasm (Takeuchi et al, 2008; Yoneyama et al, 2007; Meylan et al, 2006). 
Upon viral RNA recognition, RIG-I and MDA5 interact with a common signaling 
adaptor, mitochondria antiviral-signaling protein (MAVS, also known as IPS1) 
and activate the NF-kB and IRF3/7 signaling pathways, resulting in the 
expression of type I IFNs and proinflammatory cytokines (Rehwinkel et al, 2010). 
 
5.2: Toll-like receptors (TLRs) 
TLRs are pattern recognition receptors that recognize microbial structures as well 
as host-derived molecules that are released from injured or apoptotic cells (Kariko 
et al, 2004). TLRs are located either on the cell surface (TLR1, TLR2, TLR4, and 
TLR6) or in endosomal membranes (TLR3, TLR7, TLR8, and TLR9). Cell 
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surface TLRs form homo- and heterodimers that recognize microbial membrane 
lipids, peptidoglycans and lipopolysaccharides, which is distinct from endosomal 
TLRs, which recognize microbial nucleic acids (Kaisho et al, 2006). Of the four 
endosomal TLRs, only TLR3 recognizes dsRNA and thus is the endosomal 
counterpart to the cytoplasmic RLRs. TLR7, TLR8, and TLR9 recognize ssRNA, 
G-rich oligonucleotides, and DNA, respectively. 
TLR3 is expressed in the placenta, pancreas, lung, liver, heart, lymph 
nodes, and brain (Muzio et al, 2000; Rock et al, 1998; Zarember et al, 2002). 
TLR3 is also present in immune cells, including T lymphocytes, natural killer 
cells, macrophages, and mast cells (Hornung et al, 2002; Orinska et al, 2005; 
Tabiasco et al, 2006). Interestingly, human fibroblasts and epithelial cells express 
TLR3 on the cell surface (Matsumoto et al, 2002; Matsumoto et al, 2003). 
TLR3 shows significant homology to TLRs that sense nucleic acids 
(Iwasaki et al, 2004). It is a 125 kDa type I transmembrane receptor with an 
extracellular ectodomain (ECD), a transmembrane region, and an intracellular 
Toll/IL-1 receptor (TIR) domain. The ECD is capped by leucine-rich repeat 
(LRR) motifs and dimerize upon ligand binding (Wang et al, 2010a). X-ray 
crystallography of two TLR3 ECDs bound to dsRNA revealed that each ECD 
binds dsRNA at two sites located at opposite ends of the ECD (Liu et al, 2008). 
This study also showed that dimeric ECD is stabilized by intermolecular 
interactions at the C terminus of the protein. 
TLR3 recognizes viral dsRNA molecules that are at least 40 base pairs in 
length as well as polyriboinosinic-polyribocytidylic acid (poly(I:C)), a synthetic 
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mimic of dsRNA (Wang et al, 2010a). Poly(I:C) internalization into endosomes is 
mediated by co-receptor CD14, which then “hands over” the ligand to TLR3 
through CD14-TLR3 interactions (Lee et al, 2006). TLR3 shows preference for 
cell-associated dsRNA over soluble dsRNA. Cell-associated dsRNA also 
produces a stronger type I IFN response in tumor-specific T cells (McBridde et al, 
2006). Furthermore, RNA released from necrotic cells has been found to induce 
the activation of TLR3-mediated immunity, including the activation of dendritic 
cells (Kariko et al, 2004). 
While most TLR signaling occurs through the adaptor protein myeloid 
differentiation primary response gene 88 (MyD88), dsRNA-mediated TLR3 
signaling induces the recruitment of adaptor protein TRIF (Jiang et al, 2004). 
TLR3 interacts with TRIF through TIR-TIR domain interactions and causes TRIF 
to homodimerize through its TIR domain and C-terminal region. 
Homodimerization induces a conformational change in TRIF that exposes protein 
surfaces that are needed to bind downstream proteins (Tatematsu et al, 2010). 
After activation, TRIF recruits tumor necrosis factor receptor-associated 3 
(TRAF3), NAK-associated protein 1 (NAP1), and two kinases, TBk1 and IKK-e. 
These interactions result in the phosphorlyation and dimeraization of transcription 
factors interferon regulatory factor 3 (IRF3) and IRF7, which subsequently 
translocate into the nucleus to induce the expression of type I IFNs (Honda et al, 
2006). In a similar fashion, TRIF also interacts with receptor interacting protein 1 
(RIP1) to activate transcription factor NF-kB, which causes the expression of pro-
infammatory genes (Meylan et al, 2004). 
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5.3: RIG-I-like receptors 
The RIG-I-like family of proteins is comprised of RIG-I and MDA5, helicases 
that detect viral RNA in the cytoplasm of vertebrate cells. RIG-I and MDA5 are 
members of the DEAD (Asp-Glu-Ala-Asp) box RNA helicase family (Linder & 
Jankowsky, 2011), and contain a central helicase domain that hydrolyzes ATP 
(Fairman-Williams et al, 2010). The N terminus of RIG-I and MDA5 contain two 
tandem caspase activation and recruitment domains (CARDs) that activate 
downstream signaling proteins via binding to the mitochondrial membrane 
adaptor protein, MAVS, through CARD-CARD interactions (Berke & Modis, 
2012). RIG-I and MDA5 also contain a C-terminal domain (CTD), which is 
believed to regulate substrate binding and protein activation (Peisley et al, 2012). 
The most notable sequence differences between MDA5 and RIG-I are a 
significantly longer linker between the CARDs and the helicase domain (105 
residues in human MDA5 compared with 55 residues in human RIG-I) and the 
slightly more acidic nature of MDA5’s Hel2i domain (the last 150 amino acids of 
the helicase domain) (Peisley et al, 2012). 
MDA5 and RIG-I belong to the DEAD box RNA helicase family. This 
family of proteins forms the largest helicase family, with 37 known members in 
humans, and family members are characterized by the presence of the Asp-Glu-
Ala-Asp motif (Fairman-Williams et al, 2010). DEAD box helicases have 
essential functions in RNA metabolism that include transcription, translation 
initiation, pre-mRNA splicing, mature mRNA transport, and the stabilization of 
protein complexes on RNA (Linder et al, 2011). All DEAD box proteins consist 
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of a highly conserved helicase core with two nearly identical domains that 
resemble the bacterial recombinase A (RecA) protein (Singleton et al, 2007; 
Caruthers et al 2002). Structural and biochemical studies have shown the ATP- 
and RNA-binding sites to be localized across both RecA-like domains on many 
DEAD box helicases. These studies showed that the two domains form an open 
cleft in the absence of ligand that closes upon ligand binding. The functional 
groups that are required for ATP hydrolysis form a complex network of 
interactions in the closed conformation, and productive ATP hydrolysis can only 
occur in this closed cleft conformation (Hilbert et al, 2009). 
Despite the highly conserved structure of the catalytic core, DEAD box 
helicases perform a diverse range of biological functions (Linder et al, 2011). This 
diversity is mediated in part by auxiliary domains that flank the core and have 
different functional roles (Linder et al, 2011). In addition, DEAD box helicases 
use the energy harnessed from ATP hydrolysis to perform a variety of 
biochemical activities. For example, the RNA clamp protein eIF4AIII is essential 
for the formation of a ribonucleoprotein complex at exon-exon junctions during 
pre-mRNA splicing while it is in the ATP bound state. ATP hydrolysis occurs 
only to induce dissociation of the protein from RNA (Liu et al, 2008a). This use 
of ATP hydrolysis differs from RIG-I or Ded1, which use ATP hydrolysis to 
power translocation and local strand denaturation, respectively (Myong et al, 
2009; Yang et al, 2006). A main goal of our work was to elucidate the 
biochemical function of ATP hydrolysis in MDA5 function.  
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5.3.1: Ligand recognition by RIG-I-like receptors 
In the last ten years, much effort has focused on identifying the PAMPs that 
trigger RIG-I and MDA5 signaling. The findings indicate that MDA5 and RIG-I 
detect different but overlapping sets of viruses, suggesting that they play different 
roles in the recognition of viral molecular features (Schmidt et al, 2012). RIG-I is 
essential in recognizing negative-sense ssRNA viruses of the paramyxoviridae, 
rhabdoviridae, orthomyxoviridae, and filoviridae families and positive-sense 
ssRNA viruses of the flaviviridae family (Kato et al, 2006). RIG-I-deficient 
mouse embryonic fibroblasts (MEFs) show abolished production of IFN-β and 
inflammatory cytokine IL-6 upon infection with these viruses (Kato et al, 2005). 
In addition, infection of RIG-I depleted MEFs with negative-sense ssRNA viruses 
abrogates the nuclear translocation of transcription factor IRF3 (Loo et al, 2008). 
MDA5, on the other hand, was shown through similar gene targeting experiments 
to specifically sense picornaviruses, a family of positive-sense ssRNA viruses that 
includes the rhinovirus, echovirus, encephalomyocaditis virus, Theiler’s virus, 
and poliovirus (Kato et al, 2006). Interestingly, RIG-I and MDA5 show a 
concerted response to dsRNA reoviruses and the positive-sense ssRNA West Nile 
and Dengue viruses (Loo et al, 2008; Fredericksen et al, 2006).  
It was originally thought that the essential component for recognition by 
RIG-I is ssRNA bearing a 5’-triphosphate group (Hornung et al, 2006; Pichlmair 
et al, 2006). The 5’-triphosphate moiety is unique to viral nucleic acids since 
vertebrate RNA is either capped in the nucleus or post-translationally modified to 
remove the triphosphate. However, more recent experiments using chemically 
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synthesized RNA indicate that only dsRNA with a 5’-triphosphate is recognized 
by RIG-I (Schmidt et al, 2009). The authors suggested that previous results were 
due to unintended hairpin structures and double-stranded byproducts resulting 
from in vitro transcription. To identify the exact RNA characteristics that are 
recognized by RIG-I, a panel of RNA molecules was synthesized and tested for 
their ability to induce type-I IFN activation in mouse monocytes (Schlee et al, 
2009). The results established that RIG-I activation requires short stretches (at 
least 19 nucleotides) of RNA in double-strand conformation with a 5’-
triphosphate. Chemically synthesized 5’-triphosphate ssRNA or even 5’-
triphosphate dsRNA that contains a missing end base pair did not induce type-I 
IFN expression. These results are consistent with sequence analysis data of 
negative-sense ssRNA viruses indicating that their genomes contain blunt short 
double-stranded 5’ triphosphate RNA in the panhandle regions (Hofacker et al, 
2004). 
Recent studies have shown that RIG-I preferentially recognizes 
uridine/adenosine rich regions of RNA. Saito et al (2008) showed that poly-(U/A) 
dsRNA forms a stable complex with RIG-I and produces a greater IFN response 
when transfected into human Huh7 cells compared with other dsRNA sequences. 
This result was subsequently confirmed by Uzri et al (2009). RIG-I also exhibits 
cell type-specific induction of antiviral responses. While it is essential for the 
induction of type I IFNs in fibroblasts and conventional dendritic cells, RIG-I-
deficient plasmacytoid dendritic cells produced similar levels of type I IFNs as 
wild-type cells (Kato et al, 2005). 
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Ligand recognition requirements for MDA5 have not yet been extensively 
studied and are not well understood. Picornavirus RNA is specifically recognized 
by MDA5 and not by RIG-I. The genome of picornavirus is different from other 
families of RNA viruses because it has a protein, VPg, attached to the 5’-end of 
the viral RNA (Pathak et al, 2007). This difference has led to the hypothesis that 
RIG-I is unable to sense picornaviral RNA due to the blockage of the 5’-
triphosphate group by VPg (Wilkins et al, 2010); however, this has yet to be 
experimentally verified. MDA5 is the primary sensor of poly-(I:C). Gitlin et al 
(2006) showed that while both RIG-I and MDA5 can bind to poly-(I:C) in vitro, 
mda5-deficient mice exhibit a more severely impaired production of IFNs.  Kato 
et al (2008) subsequently showed that poly-(I:C) can be converted from an MDA5 
to a RIG-I ligand by shortening its length by RNase III treatment. This result led 
to the current hypothesis that MDA5 preferentially senses long (greater than 1 kb) 
dsRNA, whereas RIG-I recognizes shorter fragments. 
Recent experiments with recombinantly expressed human MDA5 support 
the notion that MDA5 is able to sense dsRNA length. Electrophoretic mobility 
shift assays (EMSA) revealed that MDA5 binds to 100-bp dsRNA with high 
affinity and is indiscriminate towards dsRNA termini structure. dsRNA molecules 
with 5’-monophosphate, 5’-triphosphate, 5’-OH, and 5’- or 3’- overhangs of 1, 2, 
or 12 nucleotides all bound to MDA5 with similar affinities. However, the results 
differed when the same experiments were performed with short molecules of 
dsRNA. When 12-bp dsRNA was used, MDA5 was still able to bind with high 
affinity to dsRNA molecules with 5’-monophosphate, 5’-triphosphate, 5’-OH, but 
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could no longer bind to dsRNA molecules with 5’- or 3’- overhangs (Peisley et al, 
2012). This result is consistent with recent experiments showing that an 8-bp 
dsRNA with either 5’ or 3’ overhangs do not bind the CTD of MDA5. The 
authors concluded that the blunt termini of dsRNA with or without phosphate 
groups are the structural motif recognized by the MDA5 CTD (Li et al, 2009). 
 
5.3.2: Functional analysis of RIG-I-like receptors  
ATPase activity has been shown to be critical to RIG-I function as the 
catalytically inactive K270A mutant shows abrogated antiviral signaling 
(Yoneyama et al, 2004). However, why ATPase activity is needed for RIG-I 
function is not understood. Two major hypotheses have been presented in the 
literature. One hypothesis posits that ATP hydrolysis enables conformational 
switching between active and inactive forms of RIG-I (see further discussion in 
Section 5.3.3), while the other hypothesis assumes that ATP hydrolysis is used to 
unwind dsRNA. The latter hypothesis argues that RIG-I is similar to the 
RNA/DNA helicases that unwind double-stranded nucleic acids by using ATP 
hydrolysis to power translocation along a product single strand. However, these 
RNA/DNA helicases show ATP hydrolysis activity upon binding to single-
stranded nucleic acids, whereas the helicase domain of RIG-I exhibits ATPase 
activity only upon binding to dsRNA (Yoneyama et al, 2005; Takahasi et al, 
2008; Cui et al, 2008). 
Myong et al (2009) used protein-induced fluorescence enhancement, a 
technique similar to the more widely used fluorescence resonance energy transfer, 
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to examine whether RIG-I exhibits translocation activity. By end-labeling 25- and 
40-nucleotide dsRNA with a fluorophore, RIG-I dsRNA binding events were 
monitored by increases in fluorescence intensity and dissociation events by 
decreases in fluorescence intensity. These studies revealed that in the presence of 
ATP, RIG-I translocates along the axis of dsRNA but does not unwind it. 
Interestingly, a RIG-I truncation mutant that lacks both CARDs (RIGh) showed a 
15-fold accelerated movement along the dsRNA. This finding is consistent with 
the observation that wild-type RIG-I stimulates ATP hydrolysis to a greater extent 
than the RIGh mutant (Cui et al, 2008), and supports the argument that the 
CARDs maintain RIG-I in an autosuppressed state (see Section 5.3.3).  
The mechanism of MDA5 regulation and activation is largely unknown. 
Another goal of our work was to investigate the oligomeric state and nature of 
conformational changes in MDA5 associated with viral RNA binding and the 
respective roles of ATP binding and hydrolysis in MDA5 function.  
 
5.3.3: Structural analysis of RIG-I-like receptors 
In the last few years, many groups have independently provided crystallographic 
and biophysical studies of RIG-I in its free state and bound to dsRNA. The first 
crystal structure of the regulatory CTD of RIG-I bound to a chemically 
synthesized self-complementary 12-mer 5’-ppp dsRNA revealed a binding 
stoichiometry of two CTDs per duplex, with one CTD at each end of the dsRNA. 
The 5’-ppp ends are each anchored in a basic pocket of the CTD with non-
bridging phosphate oxygens in close enough proximity to hydrogen bond to six 
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lysine side chains of the protein (Wang et al, 2010). These interactions are 
believed to account for the 10-fold higher binding affinity of RIG-I for blunt-end 
5’-ppp dsRNA compared to 5’-OH dsRNA (Lu et al, 2010). The crystal structure 
also revealed pi stacking of the 5’ nitrogenous base pair to the aromatic ring of a 
phenylalanine side chain. This interaction is believed to provide an explanation 
for the preference of RIG-I for blunt-end duplexes over ssRNA (Wang et al, 
2010). 
More recently, crystal structures were obtained for full-length RIG-I, 
deltaCTD RIG-I, and the helicase domain alone (Hel), as well as a ternary 
complex of RIG-I with an ATP analog and a 19-mer dsRNA (Kowalinski et al, 
2011). These structures, along with prior biochemical observations, have led to 
the currently accepted mechanism for RIG-I activation. In the absence of bound 
ligand, the helicase domain exists in an open conformation with the CARDs 
bound to the helicase insertion domain (Hel2i, composed of the final 150 amino 
acids of the helicase domain) and the CTD flexibly linked to the helicase. This 
conformation has since been termed the “autorepressed state”, because the tandem 
CARDs are inhibited from signaling by binding to a region of the protein itself. 
The fact that binding of the CARDs to Hel2i is strong enough to prevent signaling 
is supported by biochemical evidence. When a conserved interface residue on 
Hel2i (Phe540 in duck RIG-I) is substituted with alanine, RIG-I exhibits a 
constitutively active phenotype (Kowalinski et al, 2011). 
In the open conformation, the helicase domain is sterically hindered from 
binding dsRNA, whereas the flexible CTD is available for sensing and capturing 
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dsRNA. It is believed that the CTD samples different nucleic acids and only 
presents those for which it has a high affinity to the helicase domain for binding. 
This notion is consistent with two seemingly contradictory observations, namely 
that the CTD has a significantly higher affinity and longer off-rate for 5’-ppp 
dsRNA compared to 5’-OH dsRNA (Lu et al, 2010) and that the helicase domain 
shows little preference for 5’-ppp dsRNA over 5’-OH dsRNA (Kowalinski et al, 
2011). The final binding of dsRNA to the helicase domain induces a 
conformational change that leads to the closed state with concomitant release of 
the tandem CARDs. Since the CARDs are attached to the rest of the protein 
through a 55-amino acid linker, they are free to signal to downstream MAVS.  
Compared with RIG-I, there have been fewer structural studies of MDA5 
and little is known about the structural basis of MDA5 activation. In 2009, a 1.45 
Å resolution structure of the MDA5 CTD was determined by X-ray 
crystallography and its binding surface for dsRNA was mapped by NMR 
spectroscopy (Li et al, 2009). Although the amino acid sequence of the MDA5 
CTD is only 24% identical to that of RIG-I, the structure revealed similar folds 
that contains two four-stranded antiparallel β-sheets connected by a β-hairpin. 
Like in RIG-I, four conserved cysteine residues arranged in tetrahedral geometry 
coordinate a central zinc ion (Li et al, 2009). The zinc ion is believed to be 
essential for maintaining the fold of the CTD as mutation of the cysteine residues 
result in abrogation of RNA recognition (Cui et al, 2008). 
The solution structure of the MDA5 CTD was determined by NMR 
spectroscopy by two independent research groups (Li et al, 2009; Takahasi et al, 
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2009). Both groups were able to map the dsRNA binding surface by titration 
experiments because the ligand-free protein showed good chemical shift 
dispersion. The results revealed that, like RIG-I, MDA5 uses a highly conserved 
positively charged groove to bind dsRNA. Interestingly, superposition of the two 
CTDs showed that the patch of lysine residues responsible for binding to the 5’-
ppp moiety of dsRNA in RIG-I is replaced by neutral amino acids in MDA5. This 
difference likely explains the inability of MDA5 to discriminate between 5’-ppp 
and 5’-OH dsRNA ends. Takahasi et al (2009) also noted the absence of a critical 
phenylalanine residue in MDA5 that is conserved in RIG-I. It is thought that this 
residue anchors the position of dsRNA in RIG-I, and its absence in MDA5 is not 
yet understood. 
 
5.3.4: Type 1 diabetes and MDA5 
Type 1 diabetes (T1D) is a disorder characterized by the immune-mediated 
destruction of insulin-producing pancreatic cells (Nakayama, 2011). T1D is 
believed to develop in mid-life as a consequence of a complex interaction 
between genetic contributions and environmental factors (Forlenza, 2011). There 
are approximately 15 chromosomal loci polymorphisms associated with T1D 
(Nejentsev et al, 2007). In 2009, a series of genome-wide association studies were 
performed on over 3000 families that include one or more offspring with T1D and 
their parents. The results revealed that individuals carrying valine at position 923 
of MDA5 (CTD) have only ~50% risk of developing T1D compared to those 
carrying the wild-type amino acid isoleucine (Nejentsev et al, 2009). The minor 
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alleles of this single nucleotide polymophism (SNP) has an occurrence frequency 
of less than 3% (Nejentsev et al, 2009), suggesting that SNPs that reduce MDA5 
function decrease the risk for T1D while wild-type MDA5 function is associated 
with T1D (Liu et al, 2009). These results were subsequently confirmed by Barrett 
et al (2009). 
The finding that the I923V SNP confers a protective effect against T1D 
spurred interest in understanding the function and structure of the mutant protein. 
Functional complementation using MDA5-deficient MEFs revealed significantly 
reduced (~40%) ability to activate downstream proteins. This finding, along with 
the observation that diabetic patients have a 3.5-fold increased frequency for 
having enteroviral RNA in their blood, suggests that MDA5 aids the onset of T1D 
through viral-induced autoimmunity (Chistiakov et al, 2010). It was thought that 
the I923V mutant confers partial resistance to T1D by reducing the affinity of 
MDA5 for viral dsRNA. In contradiction, however, EMSA using 32P-labeled 
poly(I:C) indicated that the I923V mutant bound to poly(I:C) as strongly as wild-
type MDA5 (Shigemoto et al, 2009). This result was not expected as the MDA5 
CTD is associated with dsRNA binding (Shigemoto et al, 2009).  
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Chapter 6: Cooperative assembly and dynamic disassembly of MDA5 filaments 
for viral dsRNA recognition 
 
This chapter is a reprint of the following publication: Peisley, A., Lin, C., Wu, B., 
Orme-Johnson, M., Liu, M., Walz, T., and Hur, S. (2011) Cooperative assembly 
and dynamic disassembly of MDA5 filaments for viral dsRNA recognition Proc 
Natl Acad Sci USA 108:21010-21015. I contributed to this work by performing all 
the single particle electron microscopy experiments. The supplemental 
information that accompanies this publication is not reprinted here due to its large 
size.  
 
 
MDA5, an RIG-I-like helicase, is a conserved cytoplasmic viral RNA sensor, 
which recognizes dsRNA from a wide-range of viruses in a length-dependent 
manner. It has been proposed that MDA5 forms higher-order structures upon viral 
dsRNA recognition or during antiviral signaling, however the organization and 
nature of this proposed oligomeric state is unknown. We report here that MDA5 
cooperatively assembles into a filamentous oligomer composed of a repeating 
segmental arrangement of MDA5 dimers along the length of dsRNA. Binding of 
MDA5 to dsRNA stimulates its ATP hydrolysis activity with little coordination 
between neighboring molecules within a filament. Individual ATP hydrolysis in 
turn renders an intrinsic kinetic instability to the MDA5 filament, triggering 
dissociation of MDA5 from dsRNA at a rate inversely proportional to the filament 
length. These results suggest a previously unrecognized role of ATP hydrolysis in 
control of filament assembly and disassembly processes, thereby autoregulating 
the interaction of MDA5 with dsRNA, and provides a potential basis for dsRNA 
length-dependent antiviral signaling. 
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6.1: Introduction 
Effective immune defense against viral infection depends on accurate and robust 
detection of viral RNAs by pattern recognition receptors in the innate immune 
system. RIG-I and MDA5 are conserved viral RNA receptors in vertebrates, 
sharing similar domain architectures and approximately 30% sequence identity. 
They are functional in the cytoplasm and responsible for detection of viral RNAs 
present during viral infection in a broad range of tissues (Wilkins et al, 2010). 
Upon viral RNA recognition, RIG-I and MDA5 interact with a common signaling 
adaptor, MAVS and activate NF-kB and IRF3/7 signaling pathways, resulting in 
the expression of type I interferon and proinflammatory cytokines (Rehwinkel et 
al, 2010).  
Previous studies suggested that RIG-I and MDA5 recognize largely 
distinct groups of viruses through their divergent RNA specificity (Loo et al, 
2008; Kato et al, 2006). RIG-I detects a variety of positive and negative strand 
viruses through recognition of a 5′-triphosphate group and blunt ends of genomic 
RNAs (Loo et al, 2008; Baum et al, 2010; Schlee et al, 2009). By contrast, MDA5 
detects several positive strand and dsRNA viruses such as picornaviruses and 
reoviruses through recognition of dsRNA replication intermediates and genomic 
dsRNAs (Loo et al, 2008; Kato et al, 2006; McCartney et al, 2008). This viral 
RNA recognition by MDA5 is independent of 5′-triphosphate or blunt end, but 
instead depends on dsRNA length in a range of approximately 1–7 kb (Kato et al, 
2008). 
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The precise mechanism for length-dependent dsRNA recognition by 
MDA5 is poorly understood. Previous studies suggest that ATP hydrolysis could 
play an important role in both interferon signaling and RNA specificity (Wilkins 
et al, 2010; Rehwinkel et al, 2010). The current model of MDA5 (or RIG-I) 
mediated signal activation is that binding of viral RNA to MDA5 triggers ATP 
hydrolysis in the conserved helicase domain, which then alters the receptor 
conformations or accessibility of the signaling domain (a tandem caspase 
activation recruitment domain) to allow its interaction with MAVS (Wilkins et al, 
2010; Zeng et al, 2010). The proposed role of ATP hydrolysis as a conformational 
switch for signaling is supported by the requirement of ATP in the reconstituted 
signaling system of RIG-I (Hou et al, 2011; Zeng et al, 2010) and the observation 
that mutations in the active site for ATP hydrolysis either constitutively activate 
or inactivate interferon signaling by RIG-I and MDA5 (Bamming et al, 2009; 
Yoneyama et al, 2004). In addition, induction of ATP hydrolysis by dsRNA has 
been shown to correlate with stimulation of interferon signaling (Schlee et al, 
2009; Cui et al, 2008). 
It has been proposed that MDA5 (and RIG-I) forms a higher-order 
structure during viral RNA recognition for efficient antiviral signaling (Andrejeva 
et al, 2004; Saito et al, 2007; Binder et al, 2011). Receptor oligomerization or 
clustering, as demonstrated in other receptors, such as inflammasomes, Toll-like 
receptors, T- and B-cell receptors, is often important for ligand sensitivity and 
downstream signaling efficiency (Davis et al, 2011; Sigalov et al, 2010). To 
understand the assembly architecture of the postulated higher order structure and 
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a potential role for ATP hydrolysis in structural reorganization, we used a 
combination of EM, biochemical, and kinetic analyses. We demonstrate here that 
MDA5 assembles into a filamentous oligomer along the length of dsRNA and 
dynamically regulates its disassembly process through ATP hydrolysis in a 
length-dependent manner. This study provides a mechanism of how MDA5 both 
recognizes dsRNA and autoregulates its antiviral signaling potential in a dsRNA 
length-dependent manner.  
 
6.2: Results 
 
6.2.1: MDA5 binding to dsRNA is cooperative 
Antiviral signaling through MDA5 is stimulated by dsRNA but not by ssRNA or 
dsDNA (Kato et al, 2008; Ablasser et al, 2009). To examine whether the 
differential binding affinities of MDA5 are responsible for dsRNA specificity, we 
purified recombinant human MDA5 from Escherichia coli and examined its 
interaction with 112 bp dsRNA and dsDNA, and 112 nt ssRNA using an EMSA. 
These model nucleic acids were derived from MDA5 cDNA, and no significant 
secondary structure was predicted for the ssRNA (mFold). 
EMSA revealed that MDA5 is capable of high-affinity binding to dsRNA, 
dsDNA, and ssRNA with dissociation constants (Kd) of 22, 33, and 57 nM, 
respectively (Figure 6.1). Despite the comparable binding affinities between the 
nucleic acid types, only the interaction between MDA5 and dsRNA is highly 
cooperative. By EMSA, MDA5 addition to dsRNA resulted in a bimodal 
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distribution of mostly either free (RNA-only) or saturated (fully complexed) 
products (Figure 6.1A). By contrast, MDA5 complexed with ssRNA or dsDNA 
exhibits a broad distribution of intermediate sizes, indicative of less cooperative 
binding. In a quantitative analysis of the EMSA results (Figure 6.1B), the dsRNA 
binding curve is sharply sigmoidal with a Hill coefficient of 4.0, whereas the 
binding curves for ssRNA and dsDNA are more hyperbolic with Hill coefficients 
of 1.5 and 2.7, respectively. EMSA analysis of another 112 bp dsRNA with 
different sequence reveals a similar bimodal distribution of RNA upon MDA5 
binding and sigmoidal binding curve, suggesting that highly cooperative binding 
of MDA5 is dependent on dsRNA structure but not sequence. 
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Figure  6.1: Only binding of MDA5 to dsRNA is cooperative and stimulates 
ATP hydrolysis. (A) EMSA with 112 bp/nt dsRNA, ssRNA, and dsDNA. A lane 
in which approximately 50% of MDA5 is bound to the respective nucleic acid 
(red box) was chosen for each sample, and the distribution of the complexes is 
displayed in the left-hand panel. (B) The EMSA results in A were fit to the Hill 
equation to obtain dissociation constant (Kd) and Hill coefficient (Nh). Estimated 
Kd and Nh are 22 nM and 4.0 for dsRNA, 33 nM and 1.5 for ssRNA, and 57 nM 
and 2.7 for dsDNA, respectively. Plotted values are mean ± SD (n = 2). (C) ATP 
hydrolysis rates (mean ± SD, n = 4) of MDA5 (0.3 µM) free of nucleic acids, 
MDA5 bound to 112 bp/nt dsRNA, ssRNA, dsDNA, DNA– RNA hybrid (▪ 
sequence 1, □ sequence 2, see Table 6.1), IRES (1 kb), and genomic RNA 
(gRNA) (∼7 kb) of EMCV and MV. Equivalent mass concentration (4.8 µg⁄mL) 
was used for all nucleic acids. 
 
6.2.2: Only dsRNA stimulates ATP hydrolysis by MDA5 
We next asked whether the ATP hydrolysis activity of MDA5 is dependent on the 
type of bound nucleic acid. We measured the ATP hydrolysis rate of MDA5 using 
two sets of 112 bp/nt dsRNAs, ssRNAs, or dsDNAs derived from two different 
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sequences at an equivalent nucleotide concentration (4.8 µg/mL, i.e., 71.4 nM 112 
bp dsRNA). The ATP hydrolysis activity of MDA5 was strongly stimulated by 
dsRNAs, but not by ssRNAs or dsDNAs (Figure 6.1C), consistent with previous 
observations (Kang et al, 2002). A 112 bp RNA-DNA hybrid and 7 kb genomic 
ssRNAs derived from two picornaviruses, encephalomyocarditis virus (EMCV) 
and Mengo virus (MV), which contain highly structured internal ribosome entry 
sites (IRES) were also unable to stimulate ATP hydrolysis (Figure 6.1C). This 
result suggests that dsRNA is the only type of nucleic acid that supports MDA5 
ATP hydrolysis. 
 
6.2.3: MDA5 forms filamentous oligomers along the length of dsRNA 
To better understand the nature of the interaction of MDA5 with dsRNA in 
comparison with ssRNA and dsDNA, we visualized complexes of MDA5 with 
nucleic acids using negative-stain EM. We included the cross-linker reagent, 
bismaleimide (BMH), and ATP analogue, ADP-aluminum fluoride (ADP•AlF4) 
in the sample preparation to improve complex homogeneity and stability. The 
migration of the BMH-cross-linked MDA5∶dsRNA complex was identical to that 
observed for the native complex by EMSA.  
The electron micrographs of the MDA5∶dsRNA∶ADP•AlF4 complex 
revealed that MDA5 forms a filamentous oligomer upon binding to 112 bp 
dsRNA (Figure 6.2A). Rod-like oligomers were rarely observed with ssRNA and 
dsDNA, (<3% of dsRNA), and were more heterogeneous in size. Each 
nucleoprotein filament of MDA5 with 112 bp dsRNA is 32-37-nm long. RNA is 
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not directly visible in the negatively stained samples, but the agreement between 
the observed filament length and predicted length of 112 bp dsRNA (∼33 nm, 
∼2.8 Å helical rise per base pair) supports the idea that the filament is arranged 
along the length of dsRNA. To test whether the filament extends with RNA 
length, we examined the complex formed with 512 bp dsRNA. Longer filaments 
of 150-170 nm were observed, consistent with the expected length of a 512 bp 
dsRNA molecule (Figure 6.2A). Thus, dsRNA promotes MDA5 filament 
assembly along the length of dsRNA.  
To obtain a more detailed understanding of the filament assembly, we 
calculated class averages of the 112 bp complex. Each filament consists of seven 
or eight segments (Figure 6.2B). This result is in agreement with the number of 
intermediate complex bands in EMSA (Figure 6.2C), suggesting that each 
segment corresponds to the minimal binding unit. The tight packing of these 
segments along the filament is consistent with cooperative binding observed from 
EMSA. Each unit occupies approximately 1.3 helical turns of the RNA (15 bp), 
but no clear indications of helical symmetry could be detected in the averages or 
their Fourier transforms. Occasionally segments in the filaments slightly deviate 
from the central axis, causing a modest level of curvature in the filament; this 
curvature may result from heterogeneity in the ADP•AlF4 occupancy or in the 
dimer-dimer interface. A more detailed analysis of the structure was not feasible 
because of the low resolution of the averages.  
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Figure 6.2: MDA5 forms filamentous oligomers along the length of dsRNA. 
(A) Representative electron micrographs of negatively stained MDA5 in complex 
with 112 and 512 bp dsRNA in the presence of ADP•AlF4 . Representative 
particles used for averaging are circled in red. (B) Representative class averages 
of MDA5 in complex with 112 bp dsRNA. The red box in the magnified view 
corresponds to a minimum binding unit of MDA5 in EMSA (C). The number of 
binding units per complex (nb) is displayed at the bottom left for each average. 
(C) EMSA of 62, 112, and 162 bp dsRNAs with MDA5 (0.3 µM) visualized with 
SybrGold stain to enhance the intermediate complexes that are otherwise difficult 
to detect. Enumeration of intermediate complexes reveals that the full complex 
contains 4, 7–8, and 11 binding units of MDA5 for 62, 112, and 162 bp dsRNAs, 
respectively. (D) Multiangle light scattering (−OD280 and ▪ Mr estimation) 
suggests that the molecular mass of the full complexes formed on 62 and 112 bp 
dsRNAs are 854 (±43) kDa and 1,878 (±13) kDa, respectively. 
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To determine the stoichiometry of the MDA5∶dsRNA complex, we 
measured the molecular mass of the BMH-cross-linked filament using multiangle 
light scattering (MALS) (Figure 6.2D). We found that MDA5 forms complexes of 
854 kDa with 62 bp and 1,878 kDa with 112 bp dsRNA, which corresponds to 6.7 
and 15.5 MDA5 monomers per RNA molecule, respectively. From EMSA, we 
observed approximately 4 and 7-8 complex bands for 62 and 112 bp dsRNAs, 
respectively (Figure 6.2C). This result suggests that each segment in EM averages 
and each binding unit in EMSA represents an MDA5 dimer. Interestingly, our 
MALS analysis and a previous report (Cui et al, 2008) suggest that MDA5 is 
monomeric in solution, indicating that MDA5 dimerizes upon dsRNA binding. 
Although a complex of a single MDA5 monomer bound to dsRNA is often 
undetectable by EMSA with dsRNA longer than 62 bp, it is apparent with 15 bp 
dsRNA. This finding suggests that dimerization is cooperative only in the context 
of filament.  
 
6.2.4: ATP hydrolysis occurs by monomers of MDA5 throughout the filament 
The unique property of dsRNA in promoting both filament assembly and ATP 
hydrolysis by MDA5 raised the question of whether filament formation is 
required for ATP hydrolysis, and whether ATP hydrolysis of an MDA5 molecule 
depends on its position within a filament. To address these questions, we 
examined ATP hydrolysis activity of MDA5 with 15, 112, and 512 bp dsRNAs. 
To account for the low binding affinity of MDA5 to 15 bp (Kd of 949 nM) and to 
measure the intrinsic ATP hydrolysis activity of MDA5 (instead of binding or 
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dissociation kinetics which often dominate the steady-state reaction rate at low 
enzyme or substrate concentration), we measured ATP hydrolysis rates using high 
concentration of MDA5 (4 µM) or dsRNA (40 µg/mL, i.e., 10.7 µM MDA5 
binding site) that would saturate 0.6 µg/mL dsRNA or 0.3 µM MDA5, 
respectively. Use of the same total base-pair (i.e., mass) concentration also 
ensures the same amount of MDA5 binding sites for all reactions. Note that 1 µM 
would occupy 3.75 µg/mL of dsRNA regardless of the RNA length (i.e., MDA5 
dimer per 15 bp). We found that 15 bp dsRNA robustly stimulates MDA5 ATP 
hydrolysis (Figure 6.3A) and its rate is comparable to that of 112 and 512 bp. 
These observations suggest that filament formation is not required for ATP 
hydrolysis and that an individual dimer can hydrolyze ATP with little positional 
preference within a filament.  
To examine the interdependence of the ATP hydrolysis activity of the two 
MDA5 monomers in a dimeric binding unit or MDA5 molecules within a 
filament, we measured the ATP hydrolysis activity of heterodimers or 
heterofilaments formed on 15 bp or 512 bp dsRNA by a mixture of WT and 
catalytically inactive mutants. We used alanine mutants of K335 and D443, the 
two conserved residues important for ATP binding and hydrolysis (Linder & 
Jankowsky, 2011), because these mutants do not hydrolyze ATP but retain high 
affinities to dsRNA. We confirmed that WT and K335A or D443A form 
heterodimers and heterofilaments using EMSA. We premixed WT and the 
mutants at various ratios with a fixed total MDA5 concentration, and formed a 
complex with a 15 or 512 bp dsRNA with the same two conditions used in Figure 
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6.3A (Figure 6.3B). In all cases, the ATP hydrolysis rate per WT (derived from 
the relative rate in Figure 6.3B divided by the WT concentration) remained 
constant. These results suggest that the intrinsic ATP hydrolysis activity of a WT 
subunit is unaffected by the catalytic activity of its dimeric partner or neighboring 
molecules within a filament.  
 
 
 
Figure 6.3: Intrinsic ATP hydrolysis activity of MDA5 is independent of 
filament length or catalytic activity of neighboring molecules. (A) Relative 
rates of ATP hydrolysis (mean ± SD, n = 3) of MDA5 (4 or 0.3 µM) with and 
without 15, 112, and 512 bp dsRNAs (0.6 or 40 µg⁄mL, equivalent to 0.16 or 10.7 
µM MDA5 binding site), with respect to 15 bp rates. (B) Relative rates of ATP 
hydrolysis of mixtures of WT MDA5 and K335A or D443A at indicated ratios 
with total MDA5 concentration fixed at 0.3 µM. The protein mixture was 
incubated with 40 µg⁄mL (10.7 µM MDA5 binding site) of 15 or 512 bp dsRNA. 
Rates were normalized against that with 100% WT. 
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6.2.5: ATP hydrolysis by MDA5 promotes dissociation from dsRNA 
Previous studies with several helicases suggested that ATP hydrolysis can trigger 
their dissociation from RNA (Linder & Jankowsky, 2011; Cordin et al, 2006). To 
test the effect of ATP hydrolysis on the interaction between MDA5 and dsRNA, 
we performed a time-dependent EMSA, in which the time evolution of the level 
of MDA5∶dsRNA complex was monitored in the presence of a protein trap, 
heparin, which binds MDA5 but does not stimulate ATP hydrolysis. MDA5 was 
preincubated with 512 bp RNA, and the reaction was initiated by adding a 
mixture of ATP and a 166-fold excess of heparin relative to RNA. The ability of 
heparin to trap MDA5 at this ratio was confirmed from EMSA in which a 
premixture of MDA5 with heparin prevents MDA5 binding to dsRNA. In the 
absence of ATP (Figure 6.4A), MDA5∶dsRNA complex is stable with less than 
30% of conversion of total dsRNA to free dsRNA within 5 min. Similar stability 
was observed for both catalytic mutants, K335A and D443A, in the presence of 
ATP. This stability is in contrast to WT MDA5 with ATP where approximately 
50% of dsRNA was free of MDA5 within 15 s (Figure 6.4A). To examine 
whether the rapid dissociation of WT is due to hydrolysis or binding of ATP, we 
replaced ATP by a nonhydrolyzable ATP analogue, β,γ-methyleneadenosine 5′-
triphosphate (ADPCP) in the dissociation reaction. ADPCP binds to MDA5 as 
evidenced by its inhibition of ATP-hydrolysis activity but does not interfere with 
electrophoresis which is the case for ADP•AlF4. In the presence of ADPCP, 
approximately 50% of total dsRNA was converted to free RNA in 5 min, as 
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opposed to 15 s for ATP (Figure 6.4A). Thus, the ATP-dependent rapid 
dissociation WT MDA5 is primarily due to ATP hydrolysis.  
Consistent with the above result, a single-round ATP hydrolysis assay also 
revealed similar dissociation kinetics during ATP hydrolysis. We monitored ATP 
hydrolysis by MDA5 in complex with 512 bp dsRNA in the presence and absence 
of heparin. The initial rates for both reactions were comparable. However, the rate 
with heparin declined to a halt within 1 min, whereas the rate without heparin 
remained constant over 3 min (Figure 6.4B). The overlapping time interval for 
ATP hydrolysis and dissociation kinetics suggests that the rapid decrease in the 
ATP hydrolysis rate in the heparin reaction is due to MDA5 dissociation from 
dsRNA.  
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Figure 6.4: Disassembly of MDA5 filament is both ATP and RNA length-
dependent. (A) Time-dependent EMSA monitoring of MDA5∶RNA complex 
dissociation. The reaction was initiated by adding a mixture of 2 mM ATP (or 
ADPCP or no ligand) and 200 µg⁄mL heparin to MDA5 (1.35 µM) in complex 
with 512 bp dsRNA (1.2 µg⁄mL, 0.32 µM MDA5 binding site), quenched on ice at 
indicated time points and analyzed on native gel. (B) Single-round ATP 
hydrolysis kinetics (mean ± SD, n = 3) of WT MDA5 (0.1 µM) with and without 
K335A or D443A (0.1 µM) bound to 512 bp dsRNA (1.2 µg⁄mL) with and 
without heparin (hep, 200 µg⁄mL). (C) Time evolution of the ATP hydrolysis rate 
derived from the single-round kinetics (Fig. 6.10 F) of WT MDA5 (0.2 µM) 
bound to 512, 1,012, and 2,012 bp dsRNAs (1.2 µg⁄mL) using the finite difference 
method. The rates were normalized against the initial rate during the first 15 s. (D) 
Single-round ATP hydrolysis rate of WT MDA5 (0.1 µM) with K335A or D443A 
(0.1 µM) bound to 512, 1,012, and 2,012 bp dsRNAs (1.2 µg⁄mL) in the presence 
of heparin (200 µg⁄mL) during 4–10 min. No ATP hydrolysis was observed 
without the mutants during this time period. 
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6.2.6: Catalytic mutants inhibit ATP-dependent dissociation of wild-type MDA5 
from dsRNA 
To test interdependence of dissociation among individual MDA5 molecules 
within a filament, we examined the effect of K335A and D443A on ATP-
dependent dissociation of WT MDA5. We first mixed WT MDA5 with the 
mutants, and performed the single round kinetic assays using 512 bp dsRNA. 
Unlike the reaction of WT alone with heparin, which stops within 1 min, the 
reactions with K335A and D443A progressed over 4 min at a rate 70% of that of 
WT alone without heparin. This result suggests that 70% of WT MDA5 remained 
bound to dsRNA over 4 min in the presence of K335A or D443A. This  
interpretation is supported by a pull-down assay with biotinylated RNA, which 
showed that WT copurifies with dsRNA after 3 min incubation with ADPCP but 
not with ATP. Addition of K335A/D443A to the ATP reaction restores the level 
of WT copurified with dsRNA. Thus, the catalytic mutants stabilize the WT 
complex and dissociation of individual MDA5 molecules is interdependent.  
 
6.2.7: ATP-driven MDA5 dissociation is filament length-dependent 
We next asked whether ATP-dependent MDA5 dissociation depends on the 
length of the filament. If every ATP hydrolysis event were equally capable of 
dissociating an individual MDA5 molecule from both filament interiors and ends, 
the dissociation rate would be independent of the initial filament length. This 
prediction would also be true if a filament disassembles cooperatively, either as 
an entire filament or in smaller fragments, when a fraction of MDA5 monomers 
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hydrolyzing ATP at a time reaches a certain threshold that is independent of 
filament length (i.e., linearly increasing stability). Alternatively, if filament 
disassembly occurs from an end as individual monomers or dimers, or 
disassembles cooperatively with a higher threshold for longer filaments (i.e., 
nonlinearly increasing stability), MDA5 would dissociate more slowly from 
longer dsRNA. We compared the dissociation rate of WT MDA5 using the single-
round kinetic assay with 512, 1,012, and 2,012 bp dsRNAs. The time derivative of 
the single-round kinetics (Figure 6.10F) showed a more rapid reduction of the 
ATP hydrolysis rate for shorter dsRNAs with half-lives of 0.2, 0.6, and 1.3 min 
for 512, 1,012, and 2,012 bp dsRNAs, respectively (Figure 6.4C). The more rapid 
decline in the ATP hydrolysis rate with shorter dsRNAs suggests a more rapid 
dissociation of MDA5 from shorter dsRNAs, which is inconsistent with models in 
which MDA5 dissociates from the filament interiors or cooperatively with its 
threshold independent of filament length.  
To further validate the length-dependent dissociation mechanisms, we 
utilized the K335A/D443A mutants to stall the dissociation reaction, and 
compared the level of WT that remained bound to dsRNAs of different lengths 
using the single-round kinetic assay. WT was premixed with an equal amount of 
K335A/ D443A, and complexes were formed with dsRNAs of 112, 512, and 
2,012 bp at the equivalent total base-pair concentration. To ensure equivalent 
binding of WT to dsRNA at the beginning of the reaction, we used 0.2 µM 
MDA5, which is 10-fold higher than the value of Kd for 112 bp (Figure 6.1B). 
We measured ATP hydrolysis progression between 4 and 10 min during which no 
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ATP hydrolysis was observed for the WT alone reaction. In the presence of 
K335A or D443A, however, ATP hydrolysis continued during this time frame 
and the rate correlated with dsRNA length; the fold increase in the rate from 112 
to 512 bp and 2,012 bp is 4.3 and 15.4 for K335A and 2.5 and 10.7 for D443A, in 
comparison to a 4.6- and 18-fold increase in length (Figure 6.4D). In principle, if 
disassembly occurs only from a filament end, the rate ratios would be equal to or 
greater than the length ratios. The closely matching of rate and length ratios 
suggests that end disassembly could be the primary mechanism with some level of 
interior dissociation, or that the filament disassembles cooperatively with 
nonlinearly increasing stability with filament length.  
 
6.2.8: A partial loss-of-function mutant, I923V, exhibits impaired filament 
assembly and reduced kinetic stability 
A partial loss-of-function SNP variant I923V (Figure 6.5A), which has been 
associated with a reduced risk for type 1 diabetes, was reported to have reduced 
signaling activity but retain similar affinity to a dsRNA mimic, poly I:C, as WT 
MDA5 (Nejentsev et al, 2009; Chistiakov et al, 2010). We asked whether the 
reduced signaling by I923V is due to impaired filament assembly and stability. 
We found that I923V binds to 112 bp dsRNA with similar affinity but with 
reduced cooperativity (Kd of 18 nM vs. 22 nM, Hill coefficient of 1.9 vs. 4.0) 
(Figure 6.5B).  
Consistent with low cooperative binding, EM revealed that I923V is less 
efficient in filament formation with 112 bp dsRNA (Figure 6.5C). The class 
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averages revealed that the overall RNA binding modes of I923V and WT are 
similar, but the I923V complex contains 4–7 dimers rather than the 7–8 dimers 
seen in the WT complex. The histogram analysis of filament length distribution 
also indicates that 45% of the WT complexes are approximately 36 nm long, 
whereas only 15% of the I923V complexes are 36 nm and 60% are 27–31.5 nm 
(Figure 6.5D). Consistent with this finding, the molecular mass of the I923V:112 
bp dsRNA complex estimated from MALS is 209 kDa (~ 1 dimer) less than that 
of the WT complex.  
We next examined the kinetic stability of I923V using the single-round 
ATP hydrolysis assay. Both WT and I923V were complexed with 2,012 bp 
dsRNA, and the progression of the ATP hydrolysis reaction in the presence of 
heparin was monitored (Figure 6.5E). Although both reactions initiated with 
similar efficiencies, the I923V reaction reached a plateau faster than the WT 
reaction, resulting in a lower level of ATP hydrolyzed during the single-binding 
event. Rate analysis suggests that I923V dissociates from dsRNA approximately 
four times more rapidly than WT (Figure 6.5F). This finding suggests that I923V 
has a reduced kinetic stability compared with WT, and supports our hypothesis 
that extended filament formation is important for maintaining kinetic stability of 
the MDA5:dsRNA complex.  
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Figure 6.5: SNP I923V forms shorter filaments and exhibits decreased 
kinetic stability. (A) Cartoon representation of MDA5 CTD [Protein Data Bank 
(PDB) ID code 2RQB]. Residue I923, distal to the Zn coordination site but 
proximal to the C terminus, is partially solvent-exposed. (B) EMSA binding 
curves (mean ± SD, n = 2) of WT and I923V MDA5 with 112 bp dsRNA. (C) 
Representative class averages of I923V in complex with 112 bp dsRNA. The 
number of binding units (nb) present for each complex is displayed at the bottom 
right. See also Fig. 6.11D. (D) Histogram of the length distribution of complexes 
formed by WT and I923V with 112 bp dsRNA. Each length represents the median 
value of each interval. The number of binding units per complex was estimated 
from the complex length. (E) Single-round ATP hydrolysis kinetics (mean ± SD, 
n = 3) of WT and I923V (0.2 µM) bound to 2,012 bp dsRNAs (1.2 µg⁄mL) in the 
presence of heparin (200 µg⁄mL). (F) Time evolution of the ATP hydrolysis rate 
derived from E using the finite difference method. Rates were normalized against 
the initial rate during the first 15 s. 
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6.3: Discussion 
The molecular mechanism for recognition of long (>1–2 kb) viral dsRNA by 
MDA5 remains poorly understood, and our limited understanding has been 
largely inferred from knowledge of a paralogous receptor, RIG-I, despite its 
divergent RNA and viral specificity. We report here the previously 
uncharacterized architecture of a filamentous assembly of MDA5 on dsRNA, and 
its dynamic ATP-dependent disassembly to provide a mechanism of how MDA5 
both recognizes dsRNA and auto-regulates its antiviral signaling activity in a 
length-dependent manner.  
We demonstrate here that binding affinity alone is insufficient to confer 
dsRNA specificity to MDA5 with high-affinity binding observed for multiple 
types of nucleic acids. Despite low stringency nucleic acid discrimination on the 
basis of affinity, MDA5 is able to distinguish between dsRNA and other types of 
nucleic acids through cooperative filamentous assembly along the length of 
dsRNA. Analogous filament structures have been observed with RecA, which 
forms filamentous oligomers along DNA and promotes strand exchange during 
homologous recombination (Cox, 2007). MDA5 is structurally related to RecA in 
that its central helicase domain consists of two RecA-like subdomains. However, 
unlike the RecA filament whose formation requires ATP binding (Chen et al, 
2008), MDA5 filament formation does not require ATP or its analogues. We 
speculate that the C-terminal domain (CTD) of MDA5, which is absent in RecA, 
plays an important role in the cooperative assembly process of the filament. A 
partial loss-of-function mutation, I923V, within the CTD lowers both the 
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cooperativity and the extent of filament assembly without affecting the dsRNA 
affinity of MDA5 (Figure 6.5). In addition, replacement of the MDA5 CTD by the 
RIG-I CTD abolishes the cooperativity while retaining high-affinity interaction 
with dsRNA. Filament formation was recently proposed for RIG-I based on 
atomic force microscopy (Binder et al, 2011); however, we did not observe either 
filament formation of RIG-I by EM or cooperative binding by EMSA. 
We demonstrated that the MDA5∶dsRNA filament is a highly dynamic 
structure, the stability of which is tightly regulated by ATP hydrolysis. Using 
quantitative single- and multiround kinetic analysis and catalytic mutant 
interference studies, we provide evidence supporting that ATP hydrolysis occurs 
throughout the filament with little coordination between neighboring MDA5 
molecules (Figure 6.3). ATP hydrolysis-driven MDA5 dissociation, however, 
occurs in a coordinated manner as evidenced by a markedly increased stability of 
a filament upon incorporation of catalytically inactive mutants (Figure 6.4B). This 
coordinated dissociation occurs at a rate inversely proportional to the filament 
length (Figure 6.4C), suggesting that not every ATP hydrolysis event leads to 
MDA5 dissociation. We propose two mechanisms to explain this length-
dependent dissociation. First, MDA5 may dissociate from dsRNA as monomers 
or dimer pairs from filament extremities. This end dissociation could be because 
MDA5 molecules in the filament ends are less stable than those in the interiors 
due to the lack of stabilizing contacts with neighboring molecules. Based on this 
end-disassembly model, the positive effect of the catalytic mutants on the filament 
stability could be explained by the mutants capping the filament ends and 
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preventing progression of filament disassembly. Second, MDA5 may 
cooperatively dissociate from dsRNA as an entire filament or smaller fragments 
whose stability increases nonlinearly with filament length. In this model, the 
catalytic mutants may increase filament stability by increasing the threshold 
required for filament disassembly by ATP hydrolysis.  
The dual and seemingly opposing roles of ATP hydrolysis as both a 
consequence of filament formation (or dsRNA binding) and as a trigger for 
filament disassembly is reminiscent of the roles of nucleotide hydrolysis in other 
filamentous proteins, such as RecA, actin, and tubulin. These proteins utilize 
either repetitive or single-round of nucleotide hydrolysis as a counterbalance 
between filament growth and turnover (Cox, 2007; Kueh & Michison, 2009). 
Competition between the filament assembly and disassembly processes was also 
evident for MDA5 in EMSA during the ATP hydrolysis steady state, which 
revealed reduced apparent affinity in comparison without ATP. Although 
comprehensive understanding of the MDA5 filament dynamics would require 
more detailed knowledge on both assembly and disassembly processes, the 
observed length-dependent dissociation provides a basis for how MDA5 could 
self-regulate its interaction with dsRNA and thus antiviral signaling potential 
according to the underlying dsRNA length. This notion is in agreement with the 
known requirement of long (>1–2 kb) dsRNA to efficiently elicit interferon 
signaling activity of MDA5 in the cell (Kato et al, 2008). Thus, our observations 
suggest a previously unrecognized role of ATP hydrolysis in autoregulation of 
MDA5 filament growth and turnover. 
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The highly cooperative MDA5 filament formation raises intriguing 
possibilities for other antiviral functions of MDA5. As many receptors in the 
immune system cluster for effective signal transmission (Davis et al, 2011; 
Sigalov, 2010), clustering of MDA5 on dsRNA may facilitate recruitment of 
MAVS or subsequent oligomerization of MAVS, which itself was recently shown 
to form prion-like fibrillar structures during antiviral signaling (Hou et al, 2011). 
It has been proposed that recruitment of MAVS by MDA5 depends on a 
conformational change of MDA5 induced by ATP hydrolysis (Wilkins & Gale, 
2010; Hou et al, 2011). It would be interesting to test whether ATP hydrolysis by 
individual MDA5 molecules within a filament recruits MAVS and promote their 
oligomerization through induced proximity. In addition, MDA5 filament 
formation may also perform a unique antiviral effector function by limiting access 
of viral proteins to RNAs, thereby interfering with viral replication or packaging. 
Interestingly, a recent study identified MDA5, along with RIG-I, as one of the 
most broadly acting antiviral effectors (Schoggins et al, 2011). Our present 
studies provide a basis for future investigations on more detailed mechanisms and 
functions of MDA5 in antiviral defense.  
 
6.4: Materials and methods 
 
Electron microscopy. MDA5 was incubated with a 20∶1 molar ratio of MDA5 to 
112 bp dsRNA (ssRNA or dsDNA) in 20 mM Hepes, pH 7.0, 150 mM NaCl, 5 
mM ADP•AlF4, and cross-linked using 0.4 mM BMH at room temperature (RT) 
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for 30 min. Negatively stained specimens were prepared as described in Ohi et al 
(2004). Images were collected with a Tecnai T12 electron microscope (FEI) and 
processed using the SPIDER software package. 
 
Multiangle light scattering. The absolute molecular mass of the complexes 
formed by WT MDA5 or I923V with dsRNA was determined using a Superose 6 
10/300 column (GE) attached to a miniDAWN TREOS detector (Wyatt 
Technology) in 20 mM Hepes, pH 7.0, 75 mM NaCl. MDA5∶dsRNA complexes 
were prepared as for EM. 
 
Electrophoretic mobility shift assay. EMSA was performed using 5′-32P-, 3′-
fluorescein- or Cy3-labeled RNAs. Unless mentioned otherwise, 0.2 nM of 32P-
labeled RNA was mixed with the indicated amount of MDA5 in buffer A (20 mM 
Hepes, pH 7.5, 150 mM NaCl, 1.5 mM MgCl2, and 2 mM DTT) with 2 mM 
ADPCP. The mixture was incubated at RT for 10 min and were analyzed on 
BisTris native gels (Life). For time-dependent EMSA, reactions were incubated at 
37°C for indicated time period. 
 
ATP hydrolysis assay. The ATP hydrolysis rate (initial velocity) was determined 
using Green Reagent (Enzo) (Martin et al, 1985). Unless mentioned otherwise, 
MDA5 was preincubated with RNA in buffer A at 37°C, and the reaction was 
initiated by addition of 2 mM ATP. For single-round kinetic assays, a mixture of 
200 µg⁄mL heparin and 2 mM ATP was added to the reaction. For initial velocity 
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measurement, aliquots were withdrawn at five time points between 15 s and 30 
min, and were quenched with 50 mM EDTA on ice. The Green Reagent was 
added to the quenched reaction at a ratio of 9∶1, and OD650 was measured using a 
Synergy2 plate reader (BioTek). 
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Chapter 7: Other structural studies of MDA5 
 
7.1: Introduction 
Several aspects of MDA5 activation remain unclear, including the nature of the 
associated conformational changes and the precise roles of ATP and dsRNA 
binding. Since MDA5 and RIG-I have similar domain architectures and high 
sequence similarity, we hypothesized that MDA5 may be regulated in the same 
manner as RIG-I. In the absence of dsRNA, RIG-I maintains an autorepressed 
conformation, with the CARDs unavailable for signaling. In this state, the 
helicase domain adopts an open conformation, in which the three individual 
subdomains, Hel1, Hel2, and Hel2i, are arranged in a semicircle with a central 
crevice (Kowalinski et al, 2011). The tandem CARDs, linked to the helicase by a 
flexible 55-residue linker, interact with the Hel2i insertion domain through 
multiple salt bridges and hydrophobic interactions (Kowalinski et al, 2011). 
Cooperative dsRNA and ATP binding induces a large conformational change in 
the RIG-I helicase domain, with all three helicase subdomains rearranging into a 
closed conformation to create the mature binding site. This rearrangement 
disrupts the interaction between the tandem CARDs and the Hel2i subdomain, 
freeing the CARDs for signaling (Kowalinski et al, 2011). 
To gain insight into the conformational changes associated with MDA5 
activation, it is essential to obtain structural information of MDA5 alone and in 
complex with ATP. Although the crystal structure of the MDA5 CTD has been 
determined and the dsRNA-binding site has been mapped, neither the overall 
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MDA5 structure nor the structure of any other domain is known. To obtain 
structural information that would allow us to develop a model for MDA5 
activation, we used single-particle EM to visualize the structures of full-length 
MDA5, full-length MDA5 in complex with ADP.ALF4, and deltaCARD MDA5 
in complex with ADPCP. 
2D averages and MALS data revealed that MDA5 assembled onto 112bp 
dsRNA forms a filamentous complex that consists of eight stacked discs, with 
each disc being composed of an MDA5 dimer (Peisley et al, 2011). Since it is not 
clear how MDA5, which is monomeric in solution, assembles onto dsRNA as 
dimers, we also calculated a 3D reconstruction of the MDA-dsRNA complex in 
the hope that the density map of the filament would provide insight into intra- and 
inter-disc interactions that govern filament formation. 
In addition to working towards a structural model of MDA5 activation, we 
also aimed at gaining an understanding of how MDA5 senses the length of 
dsRNA. Kato et al. (2008) reported that treatment of long dsRNA (greater than 1 
kb) with RNase III converts it from an MDA5 ligand to a RIG-I ligand. This 
result suggests that MDA5 has a mechanism to measure the length of the dsRNA 
before accepting or rejecting it as an appropriate ligand. Furthermore, 
electrophoretic mobility shift assays (EMSA) revealed that MDA5 binds to 100-
bp dsRNA with high affinity and is indiscriminate of termini structure (Peisley, 
2012). dsRNA molecules with 5’-monophosphate, 5’-triphosphate, 5’-OH, and 5’- 
or 3’- overhangs of 1, 2, or 12 nucleotides all bound to MDA5 with similar 
affinities. However, when 12-bp dsRNA was used, MDA5 still bound with high 
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affinity to dsRNA molecules with 5’-monophosphate, 5’-triphosphate, and 5’-OH, 
but did no longer bind dsRNA molecules with 5’- or 3’- overhangs (Peisley, 
2012). These results suggest that the mode of MDA5 binding varies based on 
dsRNA length. We sought to understand the basis for this phenomenon by using 
single-particle EM to follow the disassembly of MDA5-dsRNA filaments. 
 
7.2: Results 
 
7.2.1: Structural characterization of monomeric MDA5 
We first used negative-stain EM to visualize recombinantly expressed human 
MDA5 in a low-salt buffer (75 mM NaCl). Multiangle light scattering (MALS) 
revealed that the majority of MDA5, a 1025 amino acid, 110 kDa protein, was 
monomeric in solution, but it also detected a small population of dimeric MDA5. 
In contrast, EM images of negatively stained MDA5 revealed particles of variable 
size and shape (Figure 7.1), and this structural heterogeneity was also seen in 
class averages (Figure 7.2). The heterogeneous size and shape of the particles 
suggested that MDA5 is prone to aggregation in low-salt buffer, and that different 
buffer conditions had to be explored to stabilize the protein. 
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Figure 7.1: Representative raw image of negatively stained MDA5 in low-salt 
buffer (75 mM NaCl). Image was taken at a magnification of 52,000x, and the 
scale bar is 100 nm. 
 
 
Figure 7.2: Averages obtained by classifying 5004 particle images of 
negatively stained MDA5 in low-salt buffer into 50 classes. The side length of 
the individual panels is 29 nm. 
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MDA5 in high-salt buffer: We tested whether a higher salt concentration in the 
sample buffer could reduce protein aggregation. Images of an MDA5 sample in 
300 mM NaCl showed indeed less aggregation in high-salt buffer (Figure 7.3), 
and class averages revealed particles with clearly resolved protein domains 
(Figure 7.4). All further studies on MDA5 were therefore performed in high-salt 
buffer. Since MALS indicated that MDA5 exists predominantly in monomeric 
form, the class averages likely represent MDA5 monomers. The averages show 
that the protein adopts an elongated and flexible conformation. Although some 
classes show long molecules, presumably representing the full-length protein 
(Figure 7.5, a), most classes show smaller molecules and resolve two to four 
domains (Figure 7.5, b-d). In these classes, the remaining domains were likely 
averaged out due to the high flexibility of MDA5. Since the tandem CARD 
domain is connected to the central helicase domain through a 105 amino acid 
linker, this is the most likely domain that was averaged out in many classes. 
The high degree of flexibility seen in soluble MDA5 suggests that MDA5 
signaling may not be regulated in a manner similar to RIG-I signaling. Unbound 
RIG-I exists in an “autorepressed” conformation, in which the tandem CARDs are 
bound to the Heli subdomain of the helicase domain. If MDA5 were regulated in 
the same way, the class averages would be expected to show proteins in a more 
defined conformation. The structural heterogeneity seen instead in averages of 
unbound MDA5 thus suggest that both the tandem CARDs and the CTD are not 
constrained.  
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Figure 7.3: Representative raw image of MDA5 in high-salt buffer (300 mM 
NaCl). Image was taken at a magnification of 52,000x, and the scale bar is 100 
nm. 
 
 
 
Figure 7.4: Averages obtained by classifying 4915 particle images of 
negatively stained MDA5 in high-salt buffer into 50 classes. The side length of 
the individual panels is 29 nm. 
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Figure 7.5: Selected averages of MDA5 in high-salt buffer. a) The largest 
particles likely represent full-length MDA5. b) MDA5 protein showing 2 
domains. c) MDA5 protein showing 3 domains. d) MDA5 protein showing 4 
domains. The side length of the individual panels is 29 nm. 
 
MDA5 with ATP analogs: We next tested whether non-hydrolyzable ATP analogs 
could reduce the heterogeneity of the MDA5 population by locking the helicase 
domain in a defined conformation. We tested both the substrate analogue ADPCP 
and the transition state analogue ADP.ALF4. Since ADP.ALF4 mimics the 
tetrahedral geometry during the transition state of ATP hydrolysis, this ATP 
analog in particular may stabilize MDA5 in a dsRNA-bound conformation. A 
comparison of the structures of MDA5 in the free and ATP analog-bound forms 
thus had the potential to reveal the conformational changes that underlie 
activation of MDA5 upon ligand binding. 
Representative raw images of negatively stained ADP.ALF4- and ADPCP-
bound MDA5 are shown in Figure 7.6. Although it was difficult to find well-
stained areas for both samples (phosphates interfere with negative staining), the 
images suggested that the conformational variability of MDA5 with bound ATP 
analogs was similar to that of free MDA5. Averages of MDA5 with bound 
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ADP.ALF4 indeed showed that the protein still adopts a flexible and elongated 
conformation (Figure 7.7). Thus, while ADP.AlF4 presumably locked the helicase 
domain into a defined conformation, this did not translate to a reduction of the 
conformational variability displayed by the full-length protein. 
 
 
Figure 7.6: MDA5 in the presence of ATP analogs. a) Raw image of MDA5 in 
high-salt buffer with 5 mM ADP.AlF4. b) Raw image of MDA5 in high-salt 
buffer with 5 mM ADPCP. Images were taken at a magnification of 52,000x, and 
the scale bars are 100 nm. 
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Figure 7.7: Averages obtained by classifying 5010 particle images of 
negatively stained MDA5 in the presence of ADP.AlF4 into 50 classes. The 
side length of the individual panels is 29 nm. 
 
DeltaCARD MDA5: To identify the position of the tandem CARDs in MDA5, we 
imaged an MDA5 construct lacking the CARD domain in the presence of 
ADP.AlF4 or ADPCP (Figure 7.8). The images suggest that the conformation 
variability of this deltaCARD construct is similar in the presence of the two ATP 
analogs and to that of the full-length protein. This impression was confirmed by 
averages of deltaCARD MDA5 in the presence of ADPCP (Figure 7.9). The 
averages show particles with a similar structural heterogeneity seen for the full-
length protein. This result suggests that the CARDs are not visible in the averages 
of full-length MDA5, most likely due to a combination of their small size and 
flexible linkage to the helicase domain. The conformational variability of MDA5 
seen in averages of full-length and deltaCARD MDA5 thus likely arises from the 
flexible linker between the helicase domain and the CTD of MDA5.  
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Figure 7.8: DeltaCARD MDA5 representative images. a) Raw image of 
deltaCARD MDA5 in high-salt buffer with 5 mM ADP.AlF4. b) Raw image of 
deltaCARD MDA5 in high-salt buffer with 5 mM ADPCP. Images were taken at 
a magnification of 52,000x, and the scale bars are 100 nm. 
 
 
Figure 7.9: Averages obtained by classifying 4479 particle images of 
negatively stained deltaCARD MDA5 in the presence of ADPCP into 50 
classes. The side length of the individual panels is 29 nm. 
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7.2.2: Three-dimensional reconstruction of the MDA5–dsRNA complex 
We demonstrated that MDA5 forms filamentous oligomers along the length of 
dsRNA (Chapter 6). 2D averages of MDA5 in complex with 112-bp dsRNA show 
a filament comprised of seven to eight stacked discs that does not appear to have 
helical symmetry. MALS revealed that each of the stacks in the nucleoprotein 
complex is an MDA5 dimer (Peisley et al, 2011). In an effort to understand the 
intra- and inter-dimer protein-protein interactions that stabilize the complex, we 
calculated a 3D reconstruction of the complex formed by MDA5 on 112-bp 
dsRNA. 10,470 particle pairs were selected from 88 50°/0° image pairs of 
MDA5–dsRNA complexes prepared by cryo-negative staining (Cheng et al, 
2006). The particles selected from the images of the untilted specimen were 
classified into 20 classes. While all class averages revealed 7 to 8 stacked discs, 
the complexes differed in the extent of bending and the presence of kinks (Figure 
7.10). The class with the most particles and best resolved fine structure were 
chosen for 3D reconstruction by the random conical tilt approach (Radermacher, 
1988). The best density map in terms of resolved structural features filtered to 30 
Å resolution is shown in Figure 7.11. The map resolves 8 stacked discs but 
provided no additional insights into the architecture of the complex compared 
with the 2D averages. 
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Figure 7.10: Averages obtained by classifying 10,470 particles of cryo-
negatively stained MDA5-dsRNA complexes selected from untilted images. 
The particles were grouped into 20 classes. The side length of the individual 
panels is 54 nm. 
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Figure 7.11: MDA5-dsRNA 3D density map. Different views of the 3D density 
map of MDA5 bound to 112-bp dsRNA at a resolution of 30 Å.  
 
7.2.3: Dissociation of MDA5 from 112-bp dsRNA 
We have shown previously that ATP hydrolysis promotes the dissociation of 
MDA5 from dsRNA. EMSA experiments revealed that 50% of complexes formed 
by MDA5 with 512-bp dsRNA dissociate fully within 15 s of incubation with 
ATP (Peisley et al, 2011). This finding is consistent with studies of several other 
helicases that require ATP hydrolysis for dissociation (Cordin et al, 2006; Linder 
et al, 2011). We have also shown that the rate of ATP hydrolysis is dependent on 
dsRNA length, where shorter dsRNAs experience a more rapid decline (Peisley et 
al, 2012). This result is consistent with two possible models for dissociation: 1) 
disassembly of MDA5 occurs mainly from the ends of the dsRNA (as opposed to 
indiscriminate dissociation from both the interior and the ends of the MDA5 
filament) or 2) MDA5 disassembly occurs cooperatively with a higher threshold 
for longer filaments. 
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We sought to further increase our understanding of MDA5 dissociation 
from dsRNA by using EM to visualize the disassembly as a function of time. 
MDA5 was preincubated with 1-kbp or 2-kbp dsRNA, and dissociation was 
initiated by adding a mixture of ATP and a 166-fold excess of heparin relative to 
RNA. The ability of heparin at this ratio to trap MDA5 released from the dsRNA 
was confirmed previously (Peisley et al, 2011). Aliquots were taken at various 
time points (0 to 100 s) and imaged by negative-stain EM (Figures 7.12 and 7.13). 
The dissociation experiments corroborated our previous biochemical results that 
indicated that the dissociation rate is inversely proportional to the filament length. 
Complete dissociation of MDA5 from 1-kbp dsRNA occurred within 60 s, 
whereas dissociation from 2-kbp dsRNA required 80 s. Images taken at 
intermediate time points also revealed that complex disassembly occurs not only 
at filament ends but also at multiple points along the nucleoprotein complex. We 
currently do not understand the requirements for the disassembly of MDA5 from 
the interior of the filament, but possible models are outlined in the discussion 
section. 
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Figure 7.12: Dissociation of MDA5 from 1-kbp dsRNA. MDA5 was pre-
incubated with 1-kbp dsRNA, and dissociation was initiated by adding a mixture 
of ATP and a 166-fold excess of heparin relative to the dsRNA. Aliquots were 
taken at defined time points and imaged by negative-stain EM. a) 0 s, b) 20 s, c) 
40 s, d) 60 s, e) 80 s, and f) 100s. Images were taken at a magnification of 
52,000x, and scale bars are 100 nm. 
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Figure 7.13: Dissociation of MDA5 from 2-kbp dsRNA. MDA5 was pre-
incubated with 2-kbp dsRNA, and dissociation was initiated by adding a mixture 
of ATP and a 166-fold excess of heparin relative to the dsRNA. Aliquots were 
taken at defined time points and imaged by negative-stain EM. a) 0 s, b) 20 s, c) 
40 s, d) 60 s, e) 80 s, and f) 100s. Images were taken at a magnification of 
28,500x, and scale bars are 200 nm. 
 
7.2.4: Averages of MDA5 complexes with ssRNA and dsDNA 
Recent studies revealed that the ATPase activity of MDA5 depends on the 
presence of dsRNA and cannot be induced by single-stranded (ss) RNA or 
dsDNA (Kang et al, 2002; Peisley et al, 2011). To see whether the specificity of 
MDA5 for the different nucleic acid species is reflected in the structure of the 
formed complexes, we used negative-stain EM to visualize the structures of the 
complexes formed by MDA5 with ssRNA and dsDNA (Figure 7.14). The images 
suggest that MDA5 can form complexes with both ssRNA and dsDNA, but the 
complexes are smaller and structurally distinct from the MDA5-dsRNA complex. 
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Averages of the MDA5-ssRNA (Figure 7.15) and MDA5-dsDNA complexes 
(Figure 7.16) showed that the complexes varied greatly in size and had no 
indication of the ordered arrangement seen in MDA5-dsRNA complexes. We 
hypothesize that the imaged particles represent abortive complexes or complexes 
that are falling apart. The observed structural differences may explain the inability 
of MDA5 bound to ssRNA and dsDNA to hydrolyze ATP. 
 
 
Figure 7.14: MDA5-ssRNA and MDA5-dsDNA complexes. a) Raw image of 
MDA5 bound to ssRNA in high-salt buffer with 5 mM ADP.AlF4. (b) Raw image 
of MDA5 bound to dsDNA in high-salt buffer with 5 mM ADP.AlF4. Images 
were taken at a magnification of 52,000x, and the scale bars are 100 nm. 
 
 150 
 
Figure 7.15: MDA5-ssRNA averages. Averages were obtained by classifying 
10,902 particles of negatively stained MDA5-ssRNA complexes into 50 classes. 
Particles were in high-salt buffer containing 5 mM ADP-AlF4. The side length of 
the individual panels is 54 nm. 
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Figure 7.16: MDA5-dsDNA averages. Averages were obtained by classifying 
10,187 particle of negatively stained MDA5-dsDNA complexes into 50 classes. 
Particles were in high-salt buffer containing 5 mM ADP-AlF4. The side length of 
the individual panels is 54 nm. 
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7.3: Discussion 
Structural information on MDA5 has thus far been limited to an atomic model of 
the CTD and the mapping of the dsRNA-binding site on the CTD by NMR 
spectroscopy. To gain insight into the conformational changes that accompany 
ligand binding and activation, we sought to use single-particle EM to capture 
MDA5 in distinct conformations representing different functional states of the 
protein. In particular, the apo-MDA5 structure and the ADP.ALF4-bound MDA5 
structure were assumed to represent the inactive and active states of the protein, 
respectively. A comparison of these two structures would thus provide insight into 
the ligand-dependent activation of the protein. We also imaged a deltaCARD 
version of MDA5 to identify the position of the tandem CARDs. Successful 
identification of the CARD domains would enable a comparison of the positions 
of the CARDs in the inactive and active forms of MDA5, potentially providing a 
structure-based explanation for the regulation of MDA5. However, the EM 
averages of all the MDA samples were very similar and showed the same 
structural heterogeneity. The structural similarity of full-length and deltaCARD 
MDA5 suggest that the CARDs are too small and/or too flexible to create a 
density in the averages, and the structural similarity of MDA with and without 
bound ADP.ALF4 suggests that this ATP analog does not lock the domains of 
MDA5 in a defined conformation. Furthermore, the lack of density for the 
CARDs indicates that they do not interact with the helicase domain, suggesting 
that the CARDs do not regulate MDA5 in a manner similar to RIG-I (through 
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autorepression). Further studies are thus required to elucidate how the CARDs 
regulate the signaling by MDA5.  
 Binding of ADP.AlF4 did not lock MDA5 in an active, ligand-bound 
conformation. This may be due to APD.ALF4 binding to MDA5 in the ALF3 
form, thus stabilizing the ground state rather than the transition state of the 
protein. Alternatively, the rigidity conferred on the helicase domain by 
ADP.ALF4 binding may simply not translate to the CARDs and CTD. 
We also used EM to further study the mechanism by which MDA5 
dissociates from dsRNA. We have previously shown that dissociation occurs at a 
rate inversely proportional to the dsRNA length, suggesting that disassembly only 
occurs through dissociation from the filament ends (Peisley et al, 2011). EM 
observation of filament disassembly confirmed the length dependence of filament 
dissociation. While MDA5 completely dissociated from 1-kbp dsRNA in 60 
seconds, it required 80 seconds for complete disassembly from 2-kbp dsRNA. 
However, unlike proposed previously, MDA5 did not only dissociate from the 
filament ends but also from multiple positions along the dsRNA. It is currently 
unclear what factors initiate MDA5 disassembly from dsRNA and define the 
positions of where disassembly occurs on the dsRNA strands. Analogous filament 
disassembly has been seen for the eukaryotic RecA analogue, RAD51. Like in 
MDA5, the central helicase domain of RAD51 consists of two RecA-like 
subdomains. RAD51 forms nucleoprotein filaments on ssRNA during 
homologous recombination, and, like MDA5, requires ATP hydrolysis for 
dissociation. The monitoring of RAD51 filament disassembly using magnetic 
 154 
tweezers revealed multiple points of disassembly (Heijden et al, 2007). The 
authors suggested that disassembly is initiated at positions, in which the RAD51 
oligomer is interrupted and contains monomers that only interact with a single 
neighboring subunit. Disassembly initiation would thus occur at sites where 
RAD51 filament extensions from the 5’- and 3’-ends of the nucleic acid meet and 
where there is a small stretch of unoccupied nucleic acid that is not large enough 
to accommodate another RAD51 monomer. Currently, we have no experimental 
evidence to suggest that MDA5 filaments disassemble in a similar fashion. We 
are in the process of performing kinetic association experiments, in which we aim 
to see multiple nucleation sites per strand of dsRNA, which would lend support to 
a RAD51-like mechanism of filament disassembly. Ultimately, however, a single 
particle approach will be required to fully understand the dynamic interaction of 
MDA5 with dsRNA. 
 
7.4: Electron microscopy experimental procedures 
 
Negatively stained samples: Negatively stained specimens were prepared by 
adsorbing 3 mL of sample to a carbon-coated EM grid, washing with two drops of 
deionized water prior to staining it with two drops of 0.75% uranyl formate. 
Images were taken on a Tecnai T12 electron microscope (FEI) equipped with a 
LaB6 electron source and operated at 120 kV. Images were recorded on imaging 
plates at a magnification of 67,000x and a defocus of –1.5 mm. Imaging plates 
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were read out with a Ditabis scanner (Pforzheim, Germany) using a step size of 
15 µm, a gain setting of 20,000 and a laser power setting of 30% (Li et al, 2009). 
 
Cryo-negatively stained samples: Cryo-negatively stained samples were prepared 
as described in Ohi et al (2004). In brief, Quantifoil grids from SPI (400 mesh 
copper holey carbon R2/1) were used. 10% glycerol was added to the sample as a 
cryo-protectant prior to deposition on the grid. Following sample adsorption and 
staining, a second carbon layer was applied to the specimen by using the 
following technique. A small square of carbon was allowed to float off carbon-
coated mica onto the surface of a third stain drop. After incubation for 20 seconds, 
the grid was used to pick up the floating carbon to complete the formation of a 
carbon sandwich. Excess stain was removed by blotting against filter paper. After 
drying, the grid was frozen in liquid nitrogen.  
 
2D average image processing: Particles were interactively selected using WEB, 
the display program associated with the SPIDER software package (Frank et al, 
1996). Particles were windowed into individual 64 x 64 pixel images, rotationally 
and translationally aligned, and subjected to 10 cycles of multi-reference 
alignment. Each round of multireference alignment was followed by K-means 
classification specifying a pre-determined number of output classes. The 
references used for the first multireference alignment were randomly chosen from 
the windowed raw images.  
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3D reconstruction: 88 pairs of micrographs at 0° and 50° were recorded. 10,470 
pairs of particles were interactively selected and windowed from the collected 
micrographs. The particles from the 0° images were then subjected to ten cycles 
of multireference alignment and K-means classification to yield 20 classes. A 
single class was used for 3D reconstruction using the random conical tilt method 
(Radermacher et al, 1987). An initial back-projection map was calculated using 
only the particles from the images of the tilted specimen. The best 10% of the 
particles from the images of the untilted specimen, as judged by cross-correlation 
with the class average, were added to the particle image stack for refinement. 
Eight rounds of angular refinement were performed in SPIDER to produce the 
final volume. The resolution of the final density map was estimated using Fourier 
shell correlation (FSC) and the FSC = 0.5 criterion.  
 
 
 
 
 
 
 
 
 
 
 
 157 
7.5: References 
Cheng, Y., Wolf, E., Larvie, M., Zak, O., Aisen, P., Grigorieff, N., Harrison, S., 
and Walz, T. (2006) Single particle reconstructions of the transferring-transferrin 
receptor complex obtained with different specimen preparation techniques. J Mol 
Biol 355:1048-1065. 
 
Cordin, O., Banroques, J., Tanner, N., and Linder P. (2006) The DEAD-box 
protein family of RNA helicases. Gene 367:17–37.  
 
Frank, J., Radermacher, M., Penczek, P., Zhu, J., Li, Y., Ladjadi, M., and Leith, 
A. (1996) SPIDER and WEB: Processing and visualization of images in 3D 
electron microscopy and related fields. J Struct Biol 116:190-199. 
 
Gipson, B., Zeng, X., and Stahlberg, H. (2007) 2dx_merge: Data management and 
merging for 2D crystal images. J Struct Biol 160:375-384. 
 
Gipson, B., Zeng, X., Zhang Z., and Stahlberg, H. (2007) 2dx – User-friendly 
image processing for 2D crystals. J Struct Biol 157:64-72. 
 
Gitlin, L., Barchet, W., Gilfillan, S., Cella, M., Beutler, B., Flavell, R., Diamond, 
M., and Colonna M. (2006) Essential role of mda-5 in type IIFN responses to 
polyriboinosinic: polyribocytidylic acid and encephalomyocarditis picornavirus. 
Proc Natl Acad Sci 103:8459-8464. 
 
Heijden, T., Seidel, R., Modesti, M., Kanaar, R., Wyman, C., and Dekker, C. 
(2007) Real-time assembly and disassembly of human RAD51 filaments on 
individual DNA molecules. Nuc Acids Res 35:5646-5657. 
 
Hou, F., Sun, L., Zheng, H., Skaug, B., Jiang, Q., and Chen, Z. (2011) MAVS 
forms functional prion-like aggregates to activate and propagate antiviral innate 
immune response. Cell 146:448-461. 
 
Kang, D., Gopalkrishnan, R., Wu, Q., Jankowsky, E., Pyle, A., and Fisher P. 
(2002) Mda-5: An interferon-inducible putative RNA helicase with double-
stranded RNA-dependent ATPase activity and melanoma growth-suppressive 
properties. Proc Natl Acad Sci 99:637-642. 
 
Kowalinski, E., Lunardi, T., McCarthy, A., Louber, J., Brunel, J., Grigorov, B., 
Gerlier, D., and Cusack, S. (2011). Structural basis for the activation of innate 
immune pattern-recognition receptor RIG-I by viral RNA. Cell 147:423-435. 
 
Li, Z., Hite, R., Cheng, Y., and Walz, T. (2009) Evaluation of imaging plates as 
recording medium for images of negatively stained single particles and electron 
diffraction patterns of two-dimensional crystals. J Electron Microsc 59:53-63. 
 
 158 
Linder, P., and Jankowsky, E. (2011) From unwinding to clamping – the DEAD 
box RNA helicase family. Nat Rev Mol Cell Biol 12:505–516.  
 
Liu, Z., Shen, J., Carbrey, J., Mukhopadhyay, R., Agre, P., and Rosen, B. (2002) 
Arsenite transport by mammalian aquaglyceroporins AQP7 and AQP9. Proc Natl 
Acad Sci USA 99:6053-6058. 
 
Leung, J., Pang, A., Yuen, W., Kwong, Y., and Tse, E. (2007) Relationship of 
expression of aquaglyceroporin 9 with arsenic uptake and sensitivity in leukemia 
cells. Blood 109:740-746. 
 
McWhirter, S., Tenoever, B., and Maniatis, T. (2005) Connecting mitochondria 
and innate immunity. Cell 122:645-647. 
 
Ohi, M., Li, Y., Cheng, Y. & Walz, T. (2004) Negative staining and image 
classification – powerful tools in modern electron microscopy. Bio Proc Online 
6:23-24. 
 
Peisley, A., Lin, C., Wu, B., Orme-Johnson, M., Liu, M., Walz, T., and Hur, S. 
(2011) Cooperative assembly and dynamic disassembly of Mda5 filaments for 
viral dsRNA recognition. Proc Natl Acad Sci USA 108:21010-21015. 
 
Peisley, A. (2012) Personal communication  
 
Pichlmair, A., Schulz, O., Tan, C., Naslund, T., Liljestrom, P., Weber, F., and 
Sousa, C. (2006) RIG-I mediated antiviral responses to single-stranded RNA 
bearing 5’-phosphates. Science 314:997-1001. 
 
Radermacher, M., Wagenknecht, T., Verschoor, A. & Frank, J. (1987) Three-
dimensional reconstruction from a single-exposure, random conical tilt series 
applied to the 50S ribosomal subunit of Escherichia coli. J Microsc 146:113-136. 
 
Radermacher, M. (1988) Three-dimensional reconstruction of single particles 
from random and nonrandom tilt series. J Electron Microsc Tech 9:359-394. 
 
Tsukaguchi, H., Weremowicz, S., Morton, C. & Hediger, M. (1999) Functional 
and molecular characterization of the human neutral solute channel aquaporin-9. 
Am J Physiol 277:F685-F696. 
 
Viadiu, H., Gonen, T., and Walz, T. (2007) Projection map of aquaporin-9 at 7 A 
resolution. J Mol Biol 367:80-88.  
 
Werten, P., Hasler, L., Koenderink, J., Klaassen, C., de Grip, W., Engel, A., and 
Deen, P. (2001) Large-scale purification of functional recombinant human 
aquaporin-2. FEBS Lett 504:200-205. 
 
 159 
Yang, B., Zhao, D., and Verkman, A. (2006) Evidence against functionally 
significant aquaporin expression in mitochondria. J Biol Chem 281:16202-16206. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 160 
Chapter Eight: Conclusion  
Bacterial and viral infections affect large numbers of people each year. While 
bacterial infections can be treated by the administration of antibiotics, the innate 
immune response is the first line of defense against viral infections. Part I of this 
thesis described my work aimed at reconstituting the enzymes that are required 
for the biosynthesis of the minimal pharmacophore of moenomycin A (MmA), a 
natural product with potent antibacterial activity. Part II of this thesis described 
single-particle EM studies of MDA5, a receptor that recognizes microbial double-
stranded RNA (dsRNA). 
MmA is a phosphoglycolipid natural product that is produced by 
Streptomyces ghanaensis (Ostash et al, 2007). Despite its excellent antibacterial 
potency, MmA has not been developed as an antibiotic because it displays poor 
pharmacokinetic properties (Wasielewski et al, 1965; Halliday et al, 2006). In 
order to enable the chemoenzymatic synthesis of unnatural MmA analogs that 
may possess better pharmacokinetic properties, I first attempted to reconstitute the 
enzymes needed to synthesize C15-farnesyl-CEF-trisaccharide and C15-farnesyl-
DEF-trisaccharide. I was able to overexpress and purify MoeGT1, MoeE5, 
MoeF5, MoeGT4, MoeGT5, and MoeM5, the enzymes required for the 
chemoenzymatic synthesis of the C15-farnesyl-CEF-trisaccharide. All enzymes 
except for MoeM5 were overexpressed and isolated from E. coli in small 
quantities. MoeM5 was overexpressed in S. lividans because the protein formed 
insoluble inclusion bodies in E. coli. I also attempted to express MoeGT3, the 
glycosyltransferase required for the attachment of the D glycan ring, but was 
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unsuccessful because of problems in the production of soluble protein in both E. 
coli and S. lividans. I was able to reconstitute the activities of all purified proteins 
except for MoeM5 and MoeGT3. The activity of MoeM5 was not tested because I 
was unable not obtain sufficient amounts of disaccharide substrates through the 
chemoenzymatic route. The reason for the low yield of MmA intermediates was 
that all enzymes expressed poorly, some yielding only 0.2 mg protein per liter of 
culture. The enzymes also exhibited a low turnover rate, such that a kcat could not 
be measured for any of the enzymes. In order to produce large quantities of MmA 
intermediates, both expression and reaction conditions would have to be 
optimized.  
I also initiated preliminary work to define the promiscuity of MoeGT1, 
MoeGT4 and MoeGT5, glycosyltransferases that attach the F and E glycan rings, 
respectively. MoeGT1 couples C15-farnesyl-phosphoglycerate with UDP-
galacturonic acid (UDP-GalUA). If MoeGT1 exhibits relaxed substrate 
specificity, one could synthesize MmA analogs with unnatural lipids. This 
possibility is of interest because the C25-moenocinol lipid tail of MmA is thought 
to contribute to the poor pharmacokinetic properties of MmA, and replacing the 
C25-moenocinol lipid with lipids with other chemical structures may improve the 
pharmacokinetic properties of MmA. Towards this goal, I synthesized a panel of 
10 phosphoglycerate lipid acceptors, so that it is now possible to test whether 
MoeGT1 accepts these lipids. I also chemoenzymatically synthesized UDP-3-
amino-N-acetyl-glucosamine (UDP-3-amino-3-doxy-GlcNAc) and assayed 
MoeGT4 for whether it could accept this sugar donor. Amino sugars are useful 
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chemical functionalities since they enable further chemical derivatization. 
Although the preliminary result was negative, it may be possible to find reaction 
conditions that would enable the enzyme to turnover. Taken together, the work on 
MmA detailed in Part I of my thesis represent significant progress towards the 
chemoenzymatic synthesis of the C15-farnesyl-CEF-trisaccharide and the first 
steps towards the exploration of enzyme promiscuity. 
Part II of this thesis concerns structural studies of MDA5, an innate 
immune receptor that recognizes dsRNA (Linder & Jankowsky, 2011). Upon 
binding to dsRNA, MDA5 interacts with the mitochondrial membrane protein, 
MAVS, which activates the innate immune response through a cascade of 
signaling events (Berke & Modis, 2012). I used single-particle EM to study the 
structures of both MDA5 alone and in complex with different nucleic acids. 
2D averages of MDA5 alone revealed that the protein adopts an elongated 
conformation and is very flexible. I attempted to stabilize the structure of the 
protein by using ATP analogs and by using an MDA5 construct that lacked the 
CARD domains. Both approaches did not improve the conformational 
homogeneity of the protein. The extreme heterogeneity displayed by MDA5 
suggests that MDA5 is not autoregulated in a similar manner as RIG-I. Structural 
studies of RIG-I have revealed that in the absence of dsRNA ligand, the CARD 
domain of RIG-I is bound to a portion of the helicase domain, thus preventing 
downstream signaling (Kowalinski et al, 2011). If MDA5 exhibits a similar type 
of autorepression in the absence of ligand, we would expect the protein to adopt a 
more homogenous conformation. Instead, our averages suggest that both the 
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CARD and C-terminal domains of apo-MDA5 are flexibly linked to the helicase 
domain and are exposed in solution. This finding raises the question of how 
MDA5 prevents signaling to IPS1 in the absence of viral infection, which would 
be an interesting topic for future studies. 
Biochemical experiments revealed that MDA5 is able to bind to dsRNA, 
ssRNA, and dsDNA with high affinity and similar dissociation constants. I used 
single-particle EM to examine the complexes formed between MDA5 and the 
different nucleic acids. When MDA5 was incubated with 112-bp dsRNA in the 
presence of ADP.AlF4, 16 MDA subunits assembled to form a linear oligomer 
consisting of eight stacked discs. I then calculated a 3D reconstruction for the 
MDA5-dsRNA complex using single-particle EM of cryo-negatively stained 
samples. The 3D map resolved the eight discs, but the flexibility of the linear 
oligomer limited the resolution of the 3D reconstruction and thus did not provide 
additional insights into the organization of the MDA5 subunits in the dsRNA-
induced oligomer.  
Filaments consisting of stacked discs were rarely observed with MDA5 
bound to ssRNA and dsDNA. Instead, these samples contained mostly amorphous 
complexes of varying sizes and shapes. We concluded that these complexes 
represent abortive complexes that do not extend to cover the entire length of the 
nucleic acid. These structural observations are in agreement with biochemical 
results showing that only the productive MDA5-dsRNA complexes hydrolyze 
ATP. We currently do not understand how filament formation and ATP 
hydrolysis activate MDA5 downstream signaling. One possibility is that 
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productive filament formation results in a conformational change in MDA5 that 
exposes the CARD domains. Alternatively, ATP hydrolysis could be used to 
effect a similar conformational change that exposes the CARD domains. In order 
to understand the mechanism of MDA5 activation, it would be interesting to 
obtain atomic structures of the MDA5-dsRNA complex, the MDA5-dsRNA-ATP 
analogue ternary complex, and potentially complexes with the downstream 
protein MAVS bound. Such structures would greatly aid in delineating the roles 
of filament formation and ATP hydrolysis in downstream signaling by MDA5.  
I also used single-particle EM to visualize the complexes that are formed 
by I923V MDA5 on dsRNA. The I923V mutation in the C-terminal domain of 
MDA5 has been associated with a reduced risk for developing Type I diabetes 
and a reduced ability for the complex to signal to downstream proteins (Nejentsev 
et al, 2009). The EM averages showed that the mutation disrupts complex 
formation. Whereas the wild-type protein contained seven to eight stacked discs 
per strand of 112-bp dsRNA, the mutant complex often contained only four to six 
stacked discs. These experiments suggest that disc stacking is required for proper 
interaction with IPS1. The mechanism of this interaction is not understood and is 
an intriguing question to explore. 
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